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iAbstract
A member of the epidermal growth factor (EGE') family; transforming
growth factor alpha (TGF-ex;)shares significant homology with EGF and
binds to the EGF receptor (EGF-R). Like EGF TGF-a plays important
roles in normal physiological processes; but, as its name signifies, it has
potent transforming ability; often associated with autocrine stimulatory
mechanisms. The purpose of this study is to investigate a possible role
for TGF -ex;and its receptor in certam human oesophageal squamous cell
carcinoma (SeC) cell lines - namely> WHCO-I, -3 and -5. The well-
studied A431 epidermoid. carcinoma cell line was used throughout for
control purposes.
As shown by radioimmunoa ssay analysis, the subject cell lines,
particularly WHCO-5, constitutively secrete appreciable quantities of'
TGF-a under unstimulated serum-free conditions. Exogenous phorbol12-
myristate 13-acetate (PMA), foetal bovine serum (FBS) and EGF
augment TGF-a. secretion to a statistically significant extent. The action
of EGF is especially noteworthy because it indicates the presence of a
functional autoinductive pathway. The high and low molecular weight
species identified in the lysates of unstimulated cells by Western blot
immunoprobe analysis are consistent with those reported in the
literature. The former (meso-TGF-a) are of particular interest because,
being cell-associated rather than secreted, they are suggestive of an
autocrine mode of action. PMA and. EGF, unlike FBS, appear to inhibit
differential glycosylation. In the case ofmes,J-TGF-tx species, they may
favour cleavage at the lys96_1ys97 cleavage site.
Cell proliferation and colony formation assays were carried out to
determine the effect of exogenous TGF-a on the proliferative and
ii
migratory behaviour of the subject cell lines. Their proliferative profiles
exhibit a lack of uniformity that has frequently been reported elsewhere
in respect of many derived cell lines. The WHCO-5 profile may be
attributable to increasing down-regulation and desensitisation of the
EGF-R. From the colony formation assays, it appears that exogenous
TGF-a inhibits the formation of colonies in the A431 and WHCO-5 cell
lines but promotes it in the WHCO~l cell line. Regarding WHCO-3,
exogenous TGF-c£seems to promote migration because it yields fewer
but larger and more diffuse colonies.
Hyperproduction ofEGF -Rs has been described as the hallmark ofSCCs.
Over ~xpression of low-affinity EGF-Rs has recently been noted in a
number of oesophageal SCC ce1llines, including WHCO-l and -3. In this
study, 1~5I-EGFcompetitive binding assays were performed to determine
the hitherto unknown number and affinity of EGF-Rs in the WHCO~5
cell line. The values obtained, which indicate the presence of
supemumary low-affinity receptors, are consistent with the consensus
that emerges from earlier research.
The vmco cell lines, especially WHCO-5, secrete relatively high levels
of TGF-a.; they also produce supernumary low-affinity EGF-Rs.
Accordingly, dot-blot DNA hybridisation analyzes were carried out to
ascertain whether these phenomena are associated with amplification
of the TGF-l'l and EGF-R genes. No evidence was found for TGF-a. gene
amplification, a result that is in agreement with the literature. On the
other hand, amplification of the EGF-R gene was found to be a
pronounced characteristic of the WHCO cells. This result is not
surprising in the light of other research into primary oesophageal
tumours and derived cell lines. A strong positive correlation was
revealed betwe en EGF -R gene amplification and protein overexpression
in the WHf!O -ell lines.
iii
'there is extensive evidence in the literature that TGF~('l interacts with
the EGF-R by means of an autocrine pathway that is regulated in
normal but deregulated in neoplastic cells, and in the latter confers a
growth advantage that is important in tumour progression. Complete
transformation typically requires more than one defect in signalling
pathways. Hence, neoplastic cells may be expected to display
overproduction of an autoerine mitogen coupled with a defect in one or
more of the mechanisms which regulate the activity of its receptor, The
experiments conducted in this study indicate that TGF~ot and its
receptor interact via. an amplified autocrine pathway in certain
oesophageal F Js of the WHCO series. They not only constitutively
produce and secrete large quantities of TGF-a but also concomitantly
overexpress low-affinity EGF-Rs, characteristics that accord with
research which suggests that TGF-a may be primarily dependent on this
class EGF-R for eliciting its mitogenic effect. Moreover, the seemingly
novel identification 0:( cell-associated meso-TGF-a is indicative of an
autocrine (or intracrine) pathway Finally, the ability of exogenous Jl]:GF
to significantlyenhan.ce the accumulation of secreted TGF-a points to
the existence of a functional autoinductive pathway. These findings
support the conclusions concerning an autocrine role for TGF-a that
have been reported in. several other studies of oesophageal SCCs.
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1Chapter 1
General Introduetion
1.1 Transforming growth factor alpha and other
growth factors
Growth factors play key roles in both normal and aberrant cellular
processes. Their many different types may be classified into five groups
or famil, ,as shown in Table I from Mercola and Stiles (198e). In
general, each type binds to its cognate receptor in a highly localised,
non-endocrine manner, thus stimulating the cell's biochemical circuitry.
The combined action initiated by different kinds of ligand - sometimes
co-operative, sometimes antagonistic - pro ..;.i.des the fine tuning of
relative proliferation and differentiation rates necessary for normal
growth and development (Goustin et al., 1986). Neoplasia is generated
by dysfunctions in the signalling pathways (Massague, 1985).
Transforming growth factor alpha (TGF -o), a member of the epidermal
growth factor (EGF) family, is significantly homologous to EGF and
binds to the EGIi' receptor (EGF-R). Like EGF, TGF-a. is. implicated in
normal physiological processes such as embryonic induction (Cross and
Dexter, 1991) and wound healing (Schultz et al., 1991); but, as its name
signifies, it has potent transforming ability, often associated with an
autocrine stimulatory mechanism (see, for example, Kaplan et al., 1982).
The aim of this st.udy in broad terms is to present and discuss my
research into the role of TGF-a. and its receptor in certain human
oesophageal squamous cell carcinoma (SeC) cell lines. This aim is
2specified more precisely in section 1.4. First, however, it is necessary to
develop a conceptual framework for two major themes that recur
intermittently throughout the ensuing Chapters: namely, the multi-step
nature of carcinogenesis and autocrine stimulation.
Table I Growth factor families
-
Group Members-
Epidermal growth factor EGl<"
TGF-a
Vaccinia growth factor, VqF
Insulin-like growth factor IGF-I
IGF-ll
Relaxin
Transforming growth factor-B TGF-Pl
TGF-~
TGF-~1.2
Inhibin-A
Inhibin-B
Activin·A
Activin AB
MUllerian inhibiting substance
Heparin-binding growth factors Acidic HBGF (acidic fibroblast growth factor,
aFGF; endothelial cell growth factor, ECGF)
:E asic HBGF. bFGF
Products of the int-2, hst, and Kaposi's Sarcoma
prctooncogenesIPlatelet-derived growth factor PDGF-A
PDGF-B (sis product)
PDGF-AB
1.2 The multi..step nature of carcinogenesis
1.2.1 Cellular oncogenes
Weinberg (1991a), on which this section is largely based, argues that a
human tumour is the end-point of a long process involving multiple
changes in genotype and phenotype. According to one attractive model,
3the cells in a tumour cell clone undergo a succession of genetic ehanges,
each of which alters the cell genome in a way that yields advantageous
growth phenotypes. Thus, the process that converts a normal cell into
an aggressively growing agent ofmalignancy is based on the conversion
of certain normal cellular genes (proto-oncogenes) into oncogenes.
Cellular oncogenes were first discovered through the study of
retroviruses. A whole class of retroviruses - those capable of rapidly
inducing tumours in infected host animals - were found to harbour
transforming genes (viral oncogenes) whose origins were ultimately
traced to similar genes residing in cellular genomes, The host cell genes
that are the progenitors of these viral oncogenes presumably control
essential aspects of normal cell physiology. The transducing ability of'
retroviruses enables them to use the host cell ~genes to transform
infected cells. More than 60 cellular genes with oncogenic potential have
now been identified (Bishop, 1991); some of the more important cognate
oncogenes are listed in 'fable II, from Weinberg (1991a).
Retroviral transduction, however, is not the only mechanism by which
specific cellular proto-oncogenes m.ay become oncogenic. Transfection-
transformation assays have proved that the same proto-oncogenes may
also be activated in animals and humans by non-viral mechanisms
involving somatic mutation. Point mutational activation ofras oncogenes
leads to the synthesis of structurally altered Ras proteins; gene
amplification has been implicated in the cases of myc, N-myc and
erbB2Ineu; and chromosomal translocations have been demonstrated in
Burkitt's lymphoma.
41.2.2 Oncogenes and multi ..step carcinogenesis
Successive genetic changes are necessary for a normal cell to become a
cancer cell. For example, tumourigenesis in mice involves three stages.
Firstly, tumour instiation can be achieved by a single mutagenic
application of carcinogen, but the skin will remain normal indefinitely
in the absence of further intervention. Tumour promotion ensues when
a promoter, such as the phorbol ester phorbol 12-ruyristate 13-acetate
(PMA) is applied. Although promoters are not mutagenic, their
application to initiated cells results in papillomatous growths. These
growths are pre-malignant, however, and disappear if promoter
treatment is suspended. Tumour progression ~ the conversion of
papillomas into autonomous growths - appears to require a second
mutagenic event. Thus, it would seem that only doubly mutated cells
develop into carcinomas.
It is not suggested, of course, that the above model describes the totality
of the cancer process. Other changes occur that enable carcinoma cells
to invade, to disseminate, to colonise distant sites as metastases and to
evade immunological defences. These later events, too, are presumably
driven by distinct changes in the tumour cell genome. Perhaps as many
as half a dozen such changes may be involved in a cell clone's transition
from normalcy to malignancy.
Tumourigenicity sometimes appears to require the co-operation of
different oncogenes (Hunter, 1991). Rat embryo fibroblasts and kidney
cells transfected by the ras oncogene are able to grow in an anchorage-
independent manner in soft agar but unable to grow indefinitely in
culture or to form tumours. Transfected by the myc oncogene, they
become immortalised but are unable to grow in soft agar or to form
5tumours. The cells become tumourigenic only when the two oncogenes
are introduced concomitantly. These results indicate that a single type
of oncogene, together with its encoded oncoprotein, is able to perturb
only a part of the cell's regulatory circuitry. 'I'he fact that the ras-like
oncogenes and the myc-like oncogenes encode cytoplasmic and nuclear
proteins respectively suggests that there are distinct cytoplasmic and
nuclear growth regulatory pathways that must be deregulated as a
necessary, though probably not a sufficient, condition for complete
cellular transformation.
Table II Examples of retrovirus-associated cellular oncogenes
Acror..ym Species of Retrovirus and tumour
origin induced -
src Chicken Bous sarcoma virus
yes Chicken Y73 sarcoma virus
ros Chicken UR2 .
mil Chicken MH2
jun Chicken AS17
myb Chicken Avian myeloblastosis virua
erb-A, erb-B Chicken Avian erythroblastosis virus
abl Mouse Abelson leukemia virus (pre-B
ceU lymphomas)
mas Mouse Moloney murine sarcoma virus
Ha-, Ki-ras Rat Harvey, Kirsten sarcoma virus
fos Mouse :F'BJ sarcoma virus
sis Woolly monkey Simian sarcoma virus
!----
fms Cat FMS feline sarcoma virus
m.yc Chicken MC29 myelocytomatosis virus
Some tumours, however, carry only a ras-like or a myc-like oncogene,
but not both. In these cases, it would appear that the presence of one or
6other. of the two types of oncogene coincides with the inactivation of a
growth-suppressor gene (or anti-oncogene), The best-known of these is
the Rb gene, whose inactivation triggers retinoblast.omas and
osteosarcomas. The evidence suggests that inactivation occurs onlywhen
both copies of the Rb gene on the paired chromosomes are disrupted.
Inactivation of an anti-oncogene is formally equivalent to activation of
an oncogene. Thus, the co-operation. necessary for tumourigenesis may
involve tr...S-c.e!!lbinedaction of either ras-like and myc-like oncogenes or
one of these coupled 'with the inactivation of an appropriate anti-
oncogene.
1.2.8 Oncogenes and growth factor autonomy
The decision by a normal cell to proliferate, quiesce or differentiate
seems to depend on exogenous stimuli, chiefly the mitogenic growth
factors and growth inhibitory factors mentioned in Section 1.1 (Cross
and Dexter, 1991). The neoplastic cell, by contrast, is characterised by
independence from the intercellular signals that govern normal
morphogenesis and maintain tissue structure. As noted in Weinberg
(1991a), there are four established mechanisms by which oncogenes can
induce cells to become independent of the exogenous growth factors
normally required for their stimulation. These mechanisms are briefly
described below.
1.2.3.1 Autocrine stimulation
Tumour cells often secrete mitogenic growth factors that stimulate them
independently of exogenous growth factors, This may result from the
alteration of growth factor genes so that they are expressed in an
7unregulated, constitutive mode. Alternatively, and more frequently,
oncogenes may constitutively turn on expression of the cell's growth
factor genes. In point is the ability of the ras-encoded p21 oncoprotein
to induce constitutive expression of TGF-a. and other growth factors.
These mechanisms are relevant to section 2.3.1 of Chapter 2.
1.2.8.2 Alterations in growth factor receptor molecules
As discussed in section 3.1.4 of Chapter 3, overexpression of the EGF~R
may stimulate cellular proliferation in a context of rsduced dependence
on exogenou: ligand. In addition, it is well known that aberrant
receptors caused by structural alteration of receptor molecules may
become constitutively active.
1.2.8.8 Alteration of cytoplasmic signalling pathways
The ras p21 and src pSO proteins, for example, receive and pass on
excitatory signals from certain receptors on the cell surface. Their
oncogenic forms, however, are constitutively active.
1.2.3.4 Alteration of nuclear signalling pathways
In the nucleus, which is the site of the ultimate cellular decisions, some
of the nuclear genes inducible by growth factors are orchestrator s of the
action of a variety of subordinate genes. Their regulatory function can
be disrupted. 'rhus, mutations of the myc proto-oncogene to an oncogene
give rise to Its constitutive expression and to consequent deregulation of
cell growth.
Finally, it should be noted that activated growth-suppressor genes may
playa similar role to that of activated oncogenes: they may induce
8autonomous growth by making a tumour CC" I unresponsive to
extracellular signals that WO'l'i,d normally terminate its proliferation
(Weinberg 1991b). One of the few examples of this mechanism known at
present is a mutant allele of the thyroid hormone recc if or gene: stem
cells carrying this defective allele are unable to differentiate and thus
may he come expc : to the transforming potential of oncogenes such as
src and crb-B.
1..3 The autocrine mechanism
1.3.1 Evidence of'autoerine secretion
Mechanisms of growth regulation by polypeptides include endocrine,
paracrine and autocrine systems. Factors, such as hormones, that enter
the circulatory system and affect distant target cells are endocrine in
nature. So is insulin-like growth factor, which is synthesised in the liver
and affects distal tissues via the; '!<')odstreaia (Lyons and Y'')ses, 1990).
According to Ohlsson and Pfeifer-Ohlsson (1987), the stimulatory
pathways of growth factors fall into two categories: paracrine (or
endocrine/paracrine) and autocrine. In the paracrine model, the cell
producing a relevant growth factor and the cell responding to the factor
are phenotypically different and spatially separated; in the autocrine
model, the cell produces both its own growth factors and its own
receptors for those factors. The autocrine system is important in normal
processes including embryogenesis, when paracrine mechanisms may be
insufficiently developed; and it. if: clearly significant in malignant
transformation by virtue of the growth advantage it confers.
The relatively autonomous nature of malignant cells, which require
fewer exogenous growth factors for optimal growth than do their normal
9counterparts, has been known for many years. Putative autocrine
secretion of a growth factor in a cancer cell was first described inrodent
cells transformed by Moloney or Kirsten murine sarcoma vivuses (Mo-
MSV and Ki-lVISV respectively). The first peptides identified in
connection with their activity are now known to have been TGF-as, and
the. relationship between release ofTGF-a and transformation has been
well established by means of experiments with temperature-sensitive
mutant rodent sarcoma viruses.
A representative early study is that of Kaplan et al. (1982).
Temperature-sensitive mutants ofMoloney and Kirsten sarcoma viruses
were used to address the question whether TGF-cxacts in an autocrine
mode in virus-induced cell transformation. At the permissive
temperature the cells were found to produce TGF-a, to have low serum
requirements, to down-regulate the EGF-R and to i~nonresponsive to
exogenous EGF. At the non-permissive temperature they did not produce
TGF-a and responded to EGF. These findings led Kaplan and his
associates to conclude that growth factors produced by cells transformed
by Ki-MSV can act ectopically and that the TGlt'-a.spresent are directly
involved in reducing the serum requirement of the cells.
As noted by Sporn and Roberts (1991).. numerous studies have now
shown that the genes for various growth factors can be made to act as
oncogenes under suitable experimental conditions, usually as part of a
retrovirus construct that will allow overexpression of the growth factor
in normal reader cells. Certain of these results suggest that autocrine
stimulation of cell growth involving TGF-a may operate in the
development ofhuman neoplasia. In section 2.1.4 ofChapter 2, reference
is made to a number of papers in which it has bec'~lquite rigorously
shown that TGF -(1, acts as an autoerme growth factor in certain cancer
cell lines, both in vitro and in vivo.
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As previously mentioned, although the growth advantage conferred by
autocrine secretion has obvious implications for carcinogenesis, the
mechanism is not confined to cancer cells but is also important in
normal cellular processes in adults as well as em}:"vas. The fact that
normal adult cells both produce and respond to TGF-o: is strong evidence
that not only transformed cells but also the proliferation of normal cells
may be regulated in an autocrine manner (Lyons and Moses, 1990). A
striking example is provided by Mead and Fa.usto (1989). who have
shown that TGF-a appears to be an autocrine physiological regulator of
liver regeneration and that its stimulatory effect on hepatocyte DNA
synthesis is inhibited by a paracrine transforming growth factor beta
(TGF-~) circuit, the balance of the two growth factors governing the
regeneration process. Another example is the interaction of TGF -c and
TGF -~ in the modulation of mouse keratinocyte proliferation in vitro
(Coffey et al., 1988).
Knowledge of the autocrine mechanism has been extended and refined
by recent research into autoinduction of growth factors, the role of
nuclear transcription factors, intracrine and juxtacrine modes of
stimulation, and the autocrine action of negative regulatory factors.
1.3.2 Autoinduction of growth factors
The ability of a growth factor to induce its own expression is a powerful
mechanism for amplification of its autocrine action. This type of positive
feedback was first demonstrated in the case of TGF~a (Coffey et al.,
1987) and was subsequently observed in several other growth factors
(Coffey et al., 1992). According to Klein et al. (1992), autoinduction of
TGF~a in human keratinocytes occurs via a pathway that necessarily
involves the tyrosine kinase of the EGFNR but does not appear to involve
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downstream mediation by protein kinase C (PKC) activation. They
speculate that autoinduction may be important in keratinocyte
proliferation, whereas induction ofTGF -cby PMAvia a PKC-dependent
pathway (Pittelkow et al., 1989; Coffey et al., 1992) may be involved in
the regulation of keratinocyte differentiation. As will be explained in
section 2.3.Z of Chapter 2, however, there is important evidence that
PKC activation is implicated in autoinduction,
Autoinduction has now been observed in the context of a variety of
normal and neoplastic cells. This finding lends support to the view that
malignancy is probably the result of some deregulation of autoerine
processes that occur, as shown for example by Mead and Fausto (1989),
in normal cells. Nuclear transcription factors appear to be implicated in
such deregulation.
1.3.3 The role of nuclear transcription factors
According to Sporn and Roberts (1991), recent studies indicate that
nuclear transcription factors have an important role in controlling the
functional activity of autocrine growth factors. For example, the Fos and
Jun proteins interact to form a dimer with potent ability to stimulate
specific gene transcription by binding at AP-1 sites on the promoter of
target genes, thus enhancing RNA polymerase activity. It has been
shown that they can regulate their own gene expression. Ithas also been
demonstrated that TGF~~ can up-regulate jun gene expression in a
manner that involves an ._L\P-l binding site on the promoter. These
findings point to the existence ot two autocrine loops that are mutually
interactive. The loss of function of a necessary interface between the
TGF-p and Fos-Jun systems may contribute to carcinogenesis.
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For the purposes of the present study, it is of interest to note that TGF-
a vigor ously induces the expression of c-fos and c-myc in C3H 10T1I2
cells (Cutry et al., 1988) and of c-fos in early post-implantation mouse
embryos (Nielsen et ala, 1991). It may well be that the mechanisms
involved are similar to those described in the preceding paragraph.
1.81.4 Intracellular autocrine stimulation
There is evidence that the mitogenic effects of a growth factor may be
achieved not only by its secretion but also by its interaction with its
receptor within some intracellular compartment, such as the Golgi
apparatus or the endoplasmic reticulum. A schematic illustration of
different possible mechanisms of antocrine growth stimulation is .
presented in Figure 1.1, which is taken from Heldin and Westermark
(13:89).
Intracrine stimulation (C in Figure 1.1) is a significant discovery
because it implies that cells subject to it would be especially resistant to
external regulation and have a particularly marked growth advantage.
However, despite the fact that it has been demonstrated in laboratory
experiments with defined cell lines and recombinant DNA constructs,
intracrine stimulation has not yet been shown to be operative in human
tumours (Sporn and Roberts, 1991).
1..8.5 Juxtaerine stimulation
Juxtacrine stimulation signifies communication between adjacent cells,
membrane-bound growth factors on the one binding to receptors on the
other, Studies with the TGF-cx precursor have shown that, in its
membrane-bound form, this molecule can establish contact with the
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EGF-R of an adjoining cell and activate the receptor's tyrosine kinase
activity (Wonget al., 1989; Brachmann at al., 1989). Anklesaria et al.
(1990), to whom the term juxtacrine is due, have shown that this form
of communication between TG"F-aand the EGF-R can promote cellular
adhesion and proliferation. It is possible that the juxtacrine ligand-
receptor link permits reciprocal rather than conventional signal
transduction (Pandiella and Massague, 1991b).
A
B
c
Figure 1.1 Schematic illustration of different possible mechanisms of autocrine growth
stimulation. (A)The growth factor is secreted and activates i; receptor at the cell surface
only. (B) The growth factor activates its receptor also in the Golgi apparatus or in the
secretory vesicles, but the ligand-receptor complex must be transported to the cell
membrane in order to transduce the mitogenic signal further. (C) The growth factor
activates its receptor and initiates all signals associated with the mitogenic response
already in the Golgiapparatus or in the secretory vesicles.
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1.3.6 Negative auiocrine regulation
TGF-~ is a potent inhibitor of DNA synthesis in almost all epithelial
cells that are common sites or carcinogenesis, and also in haematopoetic
precursor cells and T and B lymphocytes. It has a key role in the
controlled processes by which normal cells replicate and differentiate
(see, for example, Coffey et al., 1988). Malignant transformation may
ensue when cells become refractory to regulation by TGF-~ for some
reason, such as a biochemical lesion in the growth factor, its receptor or
the post-receptor signalling pathway. Accordingly, there has been much
research into the use of molecules in the steroid hormone family, such
as retinoic acid and its analogues, as agents to stimulate the synthesis,
secretion or activity of TGF-~.
As noted in Sporn and Roberts (1991), retinoic acid therapy has proved
to be highly potent in th...~treatment of acute promyelocytic leukemia
(APL). Studies of HL-60, a cell line derived from a patient with APL,
have shown that retinoic acid induces synthesis ofTG:E1-~2and the TGF-
~ receptor in these cells, which lack the receptor in their basal state.
These studies suggest that retinoic acid acts to restore a negative or
anti-proliferative autocrine loop to malignant cells. Tamoxifen, which
stimulates TGF-~l' appears to act similarly in MCF-7, a human breast
cancer cell line. Retinoic acid is effective in the prevention of cancer in
a variety of epithelia, and a clear relationship between it and
stimulation ofTGF-~2 synthesis has been established in the case of skin
cancer. In the latter case one may speculate that negative autocrine
action is involved.
Although TGF~a has generally been observed in a positive autocrine
mode, it is of interest to note that this peptide has recently been shown
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to be a potent autocrine inhibitor of GH4 pituitary tumour cell
proliferation (Ramsdell, 1991).
1.4 Aim of the present study
This study is concerned with oesophageal cancer, which is the sixth most
common cancer in the world (Cheng et al., 1992). Carcinoma of the
oesophagus is relatively common in certain parts of southern Africa
(Bradshaw and Harington, 1987), although the reasonsfbr'tts'prevalence
are a matter of speculation (Thornley et al., 1991). In Black South
Africans, oesophageal carcinoma has reached epidemic proportions since
1940, and at present is the most common cause of cancer-related deaths
(Haffejee and Bryer, 1991).
As noted by Haffejee and Bryer (1991), sces constitute 95% of primary
oesophageal malignancies. Oesophageal sec is often far advanced at the
time of its detection and as a result is generally associated with poor
prognosis, especially ifit is correlated with gastric involvement by lymph
node and in.tramural metastases (Kuwano et al., 1992). The
epidemiology, aetiology, pathology and current treatment of this
carcinoma have been described in Haffejee and Bryer (1991).
The specific aim of the present study is to report and discuss the
findings ofmy research into the possiblity that TGF-c:xacts in a positive
autocrine mode in three human oesophageal sec cell lines: namely,
WHeO-l, -3 and -5, the abbreviation WHeO signifying Witwatersrand
University human carcinoma of the oesophagus. These lines were
established from biopsies taken from middle-aged Black patients during
routine investigations of the oesophagus. The biopsies were
pathologically characterised as having a moderate degree ofkeratinocyte
16
differentiation and a squamous cell infiltration of the tissues underlying
the oesophageal epithelium. Their establishment procedures, DNA
profiles and histological characteristics have been described in Thornley
et al. (1991).
In Chapter 2. I discuss my experimental results regarding the
production, secretion and biological action ofTGF-a in the WHCO-I, ~3
and -5 cell lines. In Chapter 3, I report on the first experimental
findings regarding' the hyperproduction and affinity of EGF-Rs in
WHCO-5 cells, which may be linked with their relatively high levels of
TGF-a. secretion. Chapter 4 is concerned with a possible role for gene
amplification in overexpression ofTGF-a and EGF-Rs in the subject cell
lines. The conclusions that emerge from this study are set out in
Chapter 5, together with some thoughts on the direction of future
research.
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Chapter 2
Transforming Growth Factor Alpha
2.1 Introduction
2.1.1 Biological background
The discovery of transforming growth factors arose from the observation
that retrovirus-transformed rat kidney cells had a marked deficiency of
EGF-Rs on their surfaces, suggesting that such cells mu.st release an
EGF-like factor able to compete with EGF for binding sites. It was
thought that this factor had been identified in the medium of certain
retrovirus-transformed murine fibroblasts. If,was assumed initially that
the factor was a single peptide (De Larco and Todaro, 1978) but
subsequent analysis showed that two structurally unrelated peptides ~
TGF-(Xand TGF-p - were involved. Their generic name, transforming
growth factor, stems from the fact that they are able to reversibly
transform immortalised normal rat kidney fibroblasts in soft agar assays
(Todaro et al., 1980). Although binding to EGF-Rs is due solely to the
presence of TGF-(X, the profound morphological changes manifested by
these cells are now known to be caused by co-operative interaction
between TGF~(Xand TGF-~ (Anzano et al., 1983).
2.1.2 Structure ofTGF-a and its precursor
Secreted rrGF-(Xexists as a family of species, ranging in apparent size
from 6kd to 20kd. Species with apparent molecular weights ofmore than
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~vkd have, however, been identified (see, for example, Luetteke et al.,
1988; Van de Vijver et al., 1991). The mature and smallest form is a 6kd
species comprising 50 amino acids, as shown in Figure 2.1 from Tam. et
ala (1991).
Figure 2.1 Amino acid sequence of mature human TGF-(X.Solid boxes represent
disulphide bridges.
Mature TGF-a is about 30% homologous with EGF and this homology,
together with the three similar disulphide bridges in both EGF and
TGF-o:, provides a molecular explanation of the fact that both bind to the
EGF-R (Derynck, 1988). Analysis of the solution structure ofTGF-a by
means of nuclear magnetic resonance spectroscopy and site-directed
mutagenesis studies has led to the identification of the residues that
contribute to its complementary EGF-R binding surface (Tam et al.,
19fJl; Field et al., 1992). As shown in Figure 2.2 from Tam ei al. (1991),
these residues are clustered at one end of the TGF-a molecule. This
duster is composed of three discontinuous fragments: namely, the phe15•
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cys-leu tripeptide ofloop A; the arg42-cys-glu tripeptide ofloop C; and the
asp47~leu dipeptide of the external carboxyl sequence.
r F15Receptor-binding region
N·tenninal
domain
C-terminal
domain
ASO
Figure 2.2 Proposed receptor-recognition site of mat me human TGF-cx.It consists of part
of the A-loop [phe15CF15)-cys-leu] and C-loop [arg42(R42)-cys-glu], as well as the carboxyl
terminal peptide sequence [asp47(D47)-1eu}_
eDNA characterisation has revealed that mature TGF~a is synthesised
as an internal part of a transmembrane glycoprotein precursor,
designated pro~TGF-a (Texeid6 and Massague, 1988), that is 160 amino
acids long in humans (Derynck et al., 1984). The precursor contains an
extracellular domain of about 100 amino acids, including the amino-
terminal signal sequence, the N- and O-glycosylation sites and the
mature TGF-a; an extremely hydrophobic transmembrane domain of 23
amino acids; and a cysteine-rich cytoplasmic domain of 35 amino acids
(Bringman et al., 1987; Teixid6 et al., 1987; Massague, 1990). The
integral membrane glycoprotein properties of the precursor have been
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verified ushg metabolic labelling experiments (Bringman et al., 1987),
membrane-associated mRNA translation techniques (Teixid6et al., 1987)
and biochemical and immunocytochemical procedures involving
transfected and tumour-derived cell lines (Wonget al., 1989; Brachmann
e; al., 1989). The human TGF-a precursor is depicted in Figure 2.3.
SI~n81 sequence (re*lduea 8-22)
Glyooaylatlon alt" (r.slduee 25-27)
E1
TraOllMmbraM d(lffl81n (reslduee 99-121)
Carboxyl-terminal domain (realdU8e 125-160)
E2
E3
c
E
Figure 2.3 Schematic representation of the human TGF -ex. precursor (based on Bringman
et al., 1987). The N- and O-glycosylation sites occur within the asn-ser-thr sequence
beginning at residue 25 (Luetteke et al., 1988); El represents the ala:i'9-val"ocleavage site;
the stippled box, mature TGF-a; E2 the ala89.va190 cleavage site; and E3 the dibasie lys9a_
lys97 cleavage site.
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2.1.3 TGF-a'smaturation and processing pathway
Pro-TGF-a is translated from a 4.5 to 4.8kb mRNA (Derynck, 1987) as
an 18kd nascent polypeptide (\Vonget al., 1989).Translation ofpro-TGF-
a in uitro in the presence of microsomal membrane vesicles has shown
that this polypeptide is translocated across the endopls smie reticulum
by means of its amino terminal signal sequence (Teixidd et al., 1987).
Translocation is arrested at the hydrophobic transmembrane spanning
domain. Nascent pro-TGF-a increases in mass following post-
translational modifications; carbohydrate units are addee' v/ I.~.dnthe
endoplasmic reticulum and Golgi apparatus to the N- and 0-
glycosylation sites (Teixidoet al., 1987;Pandiella and Massague, 1991a),
and palmitate side chains are linked to cysteine residues in the carboxyl
terminus (Bringman et al., 1987). In several cell types, the extent of N-
linked carbohydrate modification varies, giving rise to a heterogeneously
glycosylated product (Teixid6 and Maesague, 1988). In Chinese hamster
ovary (CHO) cells, N- and O-glycosylat.ion are not required for the
expression of pro-TGF-« on the cell surface or the generation of soluble
TGF-a (Bringman ei al i 1987; Teixid6 et al., 1990). In retrovirally
transfe rmed rat fibroblasts, however, inhibition of N-~lycosylation
interferes with TGF-a production (Teixid6 and. Massague, 1988).
The release ofmature TGF-a from the outer domain ofhuman pro-TGF-
a occurs followingproteolytic :-lO~lVageat sequences on the carboxyl side
of alanine residues 39 and 89 (Derynek et al., 1984). The extracellular
or cell-surface proteinases responsible for this cleavage are presumed to
have elastase-like activity (Teixid6 et al., 1990) but have not yet been
identified (Choudry and Kenny; 1991). Cleavage at lysine residues 96
and 97 by an enzyme with trypsin-like activity may also '.Y.a
contributory role in some cell types (Bringman et al., 1987; 'Ieix. J and
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Massague, 1988). The proteolytic process that releases mature TGF-a is
inefficient under basal conditions in most cultured cell linea (Teixid6 et
al., 1990) and may either lead to the release ofpartiaHy processed forms
(Luetteke et al., 1988; Teixido and Massague, 1988; Teixid6 et al., 1990),
collectively designated meso-I'Gli-« (Teixid6 and Massague, 1988), or to
the accumulation ofprc~TGF-a on the plasma membrane (Teixid6et al.,
1990; Brachmann et al., 19£9). Pro-TGF-a exposed on the surface of one
cell can interact with EGF-Rs on the surface of adjacent cells and
thereby effect cell-cell adhesion (Anklesaria et al., 1990), receptor
autophosphorylation (Brachmann et al., 1989; Wong et al., 1989),
transmembrane signalling (Wong et al., 1989) a.nd mitogenesis
(Anklesaria et al., 1990).
Teixido and Massague (1988) have outlined a processing pathway in
connection with a study of retrovirally transformed rat embryo
fibroblasts. It was found that these cells release to the medium not only
mature TGF-a bu.t also a group of meso-'I JF-as of 17-20kd. The latter
were shown to correspond to the heterogeneously glycosylated
extracellular domain ofpro-TGF-a. As may be seen from Figure 2.4, the
processing of pro-TGF-a in transfected rat embryo fibroblasts appears
to involve two stages. The first leads to a meso-rrGF-« by elastase-
mediated cleavage at the alas8_va189 site, possibly preceded by trypsin-
mediated cleavage at the lys95_lys96site. The second leads to a mature
TG:H'-aby elastase-mediated cleavage of meso-TGF-o at the alanine-
valine site located in. the amino terminus.
This processing pathway appears also to be operative in the chemically-
induced rat hepatocellular carcinoma cell line JMl (Luettoke et al.,
1988) but not in CHO cells transfected with a rat pro-TGlr-o; eDNA
sequence. In the latter, cleavage at the ala88_va189site is a rate-limiting
step L'1. the generation of soluble TGF-a and is preceded by the more
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rapid cleavage at ala38·ya139 (Teixid6 et al., 1990). This cleavage-rate
discrepancy is surprising, given the similarity of the N- and C-terminal
cleavage sequences, and is not understood (Massague, 1990). [In passing,
it is pointed out that cleavage sites are shifted by one amino acid
residue towards the amino terminus in rat pro-TGF-a, which has a
length of 15£1 amino acids (Lee et al., 1985) compared with 160 amino
acids for humans].
proTGF-a mesoTGF-g
(
~ "eli'"
23 \ N,1N mature TGF-a- / (active)--
3 A
.-~ BfJc; 6f~.::JE::>
Z 88 V-e
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:::l I
:g 95
~-'
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'"Clcr; Memorane
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159l l
Figure 2.4 The conversion of membrane-bound pro-TGF-.o: into soluble, bioactive
products. Rat pro-TGF·a: is a 159··aminoacid protein with a hydrophobic sequence between
residues 97 and 120 that acts as a membrane anchor. The NHz-u'\rminal domain faces the
extracellular side of the membrane, and contains carbohydrate N··linked to asparagine 25
(~N),and O-linked carbohydrate (-0). The extracellular domain includes the 50-amino acid
sequence corresponding to mature TGF-a:. This sequence is flanked by alanine-valine
sequences (AIV).An elastase-like activity (E) cleaves at the AN site in the eOOH terminus
of the mature TGF·a: sequence, As a result, the 17-19kd heterogeneously glycosylated
meso-TGF-Il is released into the medium as a soluble, bioactive molecule. Further cleavage
of this intermediate precursor at the AN site located in tile NH2 terminus of the TGP-a:
sequence yields mature TGP·a:. A Iysine-lysine (KIK) sequence in position 95-96 of pro-
TGF-a might serve as an additional site for cleavage and release of the extracellular
domain.
Recent work on transfected CRO cells has shown that the cleavage of
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pro~TGF~ais a highly regulated process that may be acutely and rapidly
enhanced by a number of exogenous agents (Pandiella and Massague,
1991a and b). The calcium ionophore A23187 enhances cleavage by a
mechanism that depends on the influx of extracellular calcium and is
largely independent JfPKC. PMA stimulates cleavage via PKC and does
not require extracellular calcium. Serum factors enhance cleavage by a
mechanism that is largely independent of both PKC and the influx of
extracellular calcium. These three mechanisms may either affect distinct
components of the cleavage process, involving either the enzyme or its
substrate, or converge 011 a common component of the cascade of events
that activate cleavage (Pandiella ami Massague, 1991b). As noted in
Pandiella and Massague (1991c), the regulation of pro-T'Gf'-o;cleavage
represents an interesting mechanism. for the release ofhormonaUy active
factors from a cell. In addition to serving as an outlet for soluble TGF-a,
stimulation of pro-TGF-a cleavage terminates the function of this
molecule as a mediator of intercellular communication by cell-cell
contact, and could also terminate the as yet hypothetical role of pro-
TGF-a as a signalling receptor.
2..1.4 The biological activity ofTG'F-a
Expression ofTGF -o has been observed in a wide variety ofnormal cells.
During embryonic development in the mouse and rat, TGJ.i"-cxis
transiently synthesised in several tissues, including the placenta, the
uterus, the developing kidney and central nervous syste-a, the
nasopharyngeal pouch, and the optic vesicle (Derynek, 1988; Tamada et
al., 1991; Lazar and Blum, 1992). TGF-a mRNA has recently been
detected in the human placenta (Bissonnette et al., 1992), the foetal
kidney (Goodyer et al., 1991) and the foetal pancreas (Miettinen and
Heikinheimo, 1992) and its protein implicated in autocrine stimulatory
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mechanisms. The TGF -c gene is also expressed in adult animals. TGF-a
is synthesised by normal skin keratinocytes (Coffey et al., 1987), by
activated macrophages (Madtes et al., 1988; Rappolee ei al., 1988) and
by eosinophile (Wong et a; 1990; Todd et al., 1991). In cultured
keratinocytes, TGF -('f has been shown to stimulate its own expression.
This process of autoinduction has been proposed as a mechanism of
signal amplification which may be essential for the propagation of
proliferative responses throughout an organ or tissue (Lyons and Moses,
1990). Furthermore, TGF'-u mRNA is present in pituitary cells
(Samsoondar et al., 1986), rat liver cells (Mead e.n:lr A. rto, 1\'189;Evarts
et al., 1992) and in the adult mammalian brain (Kudlow et al. 1989;
Seroogy et al., 1991). In the rat liver, TGF-a plays an important role in
regeneration (Mead and Fausto, 1989)and in hepatic \'dl migration both
in vitro and in vivo (Bade and Fiendler, 1988; Evarts et al., 1992). The
presence ofTGF-a in the brain, a non-proliferative tissue, is surprising
and little understood. Although the brain cells may _'lotproliferate in
response to oncogene induction or growth factor stimulation, neurons
and glial cells throughout the brain. exhibit EGF-Rs and thereforeTGF-u
may act as a signalling peptide within the brain (see, for example, Ojeda
et at, 1990).
The foregoing suggests that TGF-a has important roles in normal
physiology - including the promotion of embryonic processes, wound
healing and organ regeneration, and.certain signalling roles in the brain.
In addition to these normal roles, however, TGF-ais critically implicated
in the process of malignant transformation, the context of its discovery
and the origin of its name.
(
Expression of the TGF-c- gene has been demonstrated in a variety of
tumours, chiefly in carcinomas, but not as yet in haematopoetic c211
lines. 'Ine consistent ex.pression of the TGF-a gene in secs and renal
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carcinomas i3 frequently accompanied by elevated levels of EGF-R
expression (Derynck et al., 1987). As noted in Karnes et ala (1992),
possibly the most convincing evidence supporting a direct role for TGF-o:
in malignancy comes from experiments in which unregulated expression
ofTGF-a in transgenic mice results in malignant changes in breast and
hepatic epithelia,
Although the autocrine stimulatory mechanism is involved in both
normal and neoplastic processes, it is perhaps particularly significant in
the latter. Addition ofTGF-a to ..MDA-MB-468breast cancer cells loads
to increased levels of EGF-R mRNA (Fernandez-Pol et al., 1989).
Furthermore, addition ofEGIi' or phorbol esters to these cells results in
the concurrent accumulation of TGF-a and EGF-R mRNA, thus
promoting autocrine growth (Bjorge et al., 1989).An antoerine function
for TGF-a in malignancy has been rigorously demonstrated in many cell
lines. These include lines derived from ovarian adenocarcinomas
(Morishige et al., 1991; Kuraehi et al., 1991); androgen-independent
prostatic carcinomas (Hofer et al., 1991); and, which is of particular
relevance to the present study, oesophageal sees (Yoshida et al., 1990;
Reiss et al., 1991). These studies all indicate that TGF-o:and its receptor
act in an autocrine mode in vitro; the paper by Kurachi et al. (1991)
shows that they can act similarly in vivo. Because human cancer results
from multiple genetic lesions, it is likely that growth factor autocrine
loops act synergistically with other molecular perturbations in the
pathogenesis and progression of the disease (Stromberg et al., 1992).
(
2.1.5 Comparative biological activity ofTGF-a and
EGF
Jiven that TGF-a and EGF both bind to the EGF-R, the question arises
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whether the two growth factors are functionally equivalent.
It should be noted that comparative studies have focused on EGF and
mature TGF-a (Derynck, 1988). The "twogrowth factors have similar
activity in some assays. For example, they are about equivalent in their
ability to stimulate DNA synthesis in various cell lines, to induce
anchorage independence (in the presence of serum and TGF-~) in
immortalised rodent fibroblasts, and to induce eyelid opening in newborn
mice,
In other assays, however, EGF and TGF-a have been found to give rise
to different responses. In most of these, TGF-u appears to have greater
potency than EGF, although some other differences may be qualitative.
Thus, TGF-a. seems to have a greater ability than EGF to cause
membrane ruffling, its effects being enhanced. by TGF-~, whereas that
ofEGF is reduced (Myrdal et al., 1986). TGF-a is more active than EGF
in the induction of monolayer colony formation of epidermal cells, an
event that in tum depends on cell migration and proliferation
(Barrandon and Green, 1987). Both EGF and TGF-a; can induce
neovascularisation in an in vivo assay, but TGF-a is the more potent
(Schreiber et al., 1986). TGF-a is also more potent than EGF in the
release of Ca~+ from bones in culture (Ibbotson et al., 1986).
(
It appears, then, that TGF-a is a superagonist of EGF in several
systems, but that in others it may have qualitatively distinct activities.
Certain arguments have been put forward to explain these differences.
As noted in Lewis et al, (1990), it is possible that these growth factors
interact with their common receptor in different ways or that they might
cause different conformational changes in the receptor. It has been
established that the two ligand-receptor complexes are processed
differently within the cell (Decker, 1990; Ebner and Derynck, 1991).
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Furthermore, the possibility of a distinct TGF~a receptor in some cell
types cannot be excluded (see, for example, Chalazonitis et al., 1992).
2.1.6 Aim. of Chapter 2
This Chapter has a twofold aim. Firstly, I propose to investigate the
production and secretion of TGF-a by A431, WHCO-I, -3 and -5 cells
under unstimulated and stimulated conditions, using Western blot and
radioimmunoassay analyses. Secondly, I explore the biological action of
exogenous mature TGF-(l on the subject cell lines using proliferation and
colony formation assays.
2.2 Materials and Methods
2.2.1 Routine cell culture
The A431, WHOa-I, -3 and -0 sec cell lines were grown in surface
culture at 3Te ill a humid atmosphere of 5%CO2 and 95% air. The lines
'Heremaintained on basal cell culture medium comprising a three to one
mixture of Dulbecco's modified Eagles medium and Ham's FI2
(DMEMlFI2), plus 10% foetal bovine serum (FBS, Hyclone). Cell
cultures were fed twice a week and passaged prior to confluence using
0.5% trypsinlO.I% EDTA in sterile phosphate buffered saline (PBS, pH
7.6; see section Al of Appendix A).
2.202 Radioimmunoassay for secreted TGF-a,
2.2.2.1 Collection of conditioned media
Basal cell culture media were aspirated and the cell monolayers washed
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with PBS. After a 4 hour preincubation inDMEMlF12. which was then
removed, 10ml of fresh DME:MIF12were added to each culture dish and
left for conditioning at 37°C over a period of 20 hours. In those cultures
that received stimulatory agents, EGF (10ng/mI, Sigma) was added at
the beginning of the 20 hour conditioning period (Coffeyet al., 1987;
Pittelkow et al., 1989), and PMA (500nM, Sigma) and FBS (10%,
Hyclone) were added 15 minutes prior to the end of this period
(Pandiella and Massague, 1991a and b). The conditioned media were
later assayed for TGF-:~ontent to _- i~ tIlt::levels ofunstimulated and
stimulated secretion per million cells. The average numbers of viable
cells present at the beginning and at the end of the conditioning period
were quantified haemocytometrically by trypan blue exclusion
(Anklesar.u et al., 1990).
All conditioned media were collected and clarified by centrifugation in
the presence of 0.02ml 1M HEPES plus O.036mJO.028MP~dSF per ml
conditioned medium and stored at -20°C.With regard to the procedure
described in Hanauske et al. (1987), conditioned medium samples were
dialysed at 4°C against 1% acetic acid using 3.5kd cut-off dialysis
membrane (Spectra/Per) and then lyophilised. Dialysed samples were
subsequently reconstituted in tris-buffered saline (TBS, pH 8.5;
Biomedical Technologies Inc.) to a final concentration of 10 times for use
in a radioimmunoassay.
2.2.2.2 Bo-dioimmunoaseay and statistical analyei»
The experiment was designed to determine whether the chosen cell lines
secrete TGF-a under unstimulated and stimulated conditions and, if so,
whether the differences between the levels of the latter and the former
were statistically significant. The quantity of TGF-a. present in the
medium conditioned by unstimulated and stimulated cells was
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determined using a sensitive and highly specific radioimmunoassy kit
(Biomedical Technologies Inc.) according to the manufacturer's
instructions (see section A2.1 of Appendix A). Using standard curves
with recombinant TGF-a, experimental and control 125I-TGF-a gamma
counts were expressed as pieagram equivalents of secreted TGF -c per
million cells (see section A2.2 ofAppendix A). The standard curves were
linear for TGF -e concentrations between 0 and O.30ng/mI, the range in
which the experimental logo values were observed. Linear regression
equations basen on this range had extremely high coefficients of
correlation and very small standard errors. Non-specific binding was less
than 4% in all cases.
Statistical analysis was directed towards determining whether mean
experimental gamma counts differed from those of the pertinent controls
in a directionally significant (one-tailed) sense at a 5% (that is pSO.05)
ievel of confidence or better. The param.etric Student t test for
independent samples was used for this purpose where the variance-ratio
F test permitted, failing which the corresponding Mann-Whitney U test
(Siegel, 1956) was used. In all cases it was found that the results were
significant at a 5% level of confidence or better. One-tailed tests were
deemed to be valid because, on theoretical grounds, one could predict
that mean experimental gamma counts would be lower than those of the
pertinent controls. In virtually all cases, however, the results are
statistically significant at the 5% level under a two-tailed test.
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2.2.8 Western blot and immunoprobe analysis of
endogenous TGF-a
2.2.3.1 Cell lysate preparation
Unstimulated and. stimulated cell monolayers were briefly rinsed with
PBS, det: .hed by scraping in detachment solution (see section A3 of
Appendix A) and transferred to 10mI centrifuge tubes. The cells were
pelleted by centrifugation for five minutes at 1000 rpm in an MSE
bench-top centriguge. After aspirating the detachment solution, Im1 of
electrophoresis sample buffer (see section A4 of Appendix A) was added
to each tube and the cell pellets were dispersed by vortexing. The cells
were lysed by boiling the cell mix for 5 minutes and the lysates stored
at -20°0 until required.
2.2.3.2 Protein electrophoresis and electroelution
Proteins within the CElli lysate samples were separated by
electrophoresis at 28mA and goC in denaturing 10-20% gradient SDS
polyacrylamide gels (see sections A5.1 and A5.2 of Appendix A)
according to the method of Laemmli (1970). The proteins were then
transferred to nitrocellulose sheets (0.45 micron Hybond-C, Amersham)
by electro elution in transfe • buffer (see section A5.3 of Appendix A) at
400mA and 5°0 for approximately 75 minutes (Towbin et al., 1979), Low
molecular weight markers (Pharmacia) were used for calibration
purposes.
2.2.3.3 Immunoprobe analysis
The electroeluted nitrocellulose sheets were immersed in blocking buffer
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(see section A6 of Appendix A) for 1 hour and then incubated for
between 2 and 4 hours in an anti-human TGF-a primary antibody
solution. The nitrocellulose sheets were subsequently incubated in a
horse-radish peroxidase-conjugated antibody solution for 1 to 2 hours.
Before and after the antibody incubations the sheets were washed for
2xl0 minutes in TBS Tween- 20 (TBST, see section A7 of Appendix A).
The primary and secondary antibodies used, which are described in
detail in section AS of Appendix .A, were diluted in TBST. Finally, the
nitrocellulose sheets were developed in a 4-chloro-l-napthol substrate
solution (see section A9 of Appendix A).
2.2.4 In vitro effects of exogenous TGF..(J.·
2.2.4.1 Cell proliferation assays
The methodology followed was based on that described in Markowitz et
al. (1990) and Chen et al. (1991). Cells were plated out into 24 well
tissue culture plates (Nunc) at a density of 5xl0~ cells/well in
DMEMlF12 plus 5% FBS. After approx'ruately 18 hours, the medium
was aspirated and replaced with Im11wellof DMEMlF12. Twenty four
hours later, this medium was removed and replaced with 0.5m11wellof
D1vIEMlF12containing 0.1 to 100ng/ml of recombinant mature human
TGF-a (Sigma). Control points received O.Sml/wellDMEMJF12 without
any growth factor supplement. The number ofviable cells was quantified
haemocytometrically by trypan blue exclusion 48 hours after growth
factor addition.
2.2.4.2 Colony formation dsays
Cells were plated out in 6cm tissue culture dishes (Nunc) at a density
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of 103 cells/dish in DMEMlF12 plus 5% FBS. After colonies had
developed to a size of approximately 15 cells, 10ng/mI ofTGF-u (Sigma)
was added to the "experimental" ill ~'es but not to their controls. Eight
days after this step, the medium waD tspirated and the dishes briefly
rinsed with PBS. The cells were then fixed, using formal-PBS (4%
formaldehyde in PBS), and the colcuies stained with PAGE-blue
biological stain.
2.3 l"'tsuits and Discussion
2.3.1 Constitutive production and secretion of
TGF-a
Constitutive secretion of TGF -c has been demonstrated in numerous
cancer cell lines, including those derived from ovarian carcinomas
(Stromberg et al., 1992) and colon adenc . cinomas (Karnes et al., 1992).
Secretion of TGF-a by the A431 epidermoid carcinoma cell line, used
here as a positive control, has been reported by a number of researchers
(Derynck et al., 1987; Reiss et al., 1991; Van de Vijver et al., 1991).
However, a recent study by Cardinali et al. (1992) failed to detect soluble
TGF -€X in. the medium conditioned by these cells over a period of 72
hours. A surprising finding of this study was the ability of suramin, a
chemotherapeutic agent" to stimulate secretion markedly. A recent
report by Reiss et al, (1991) has demonstrated that constitutive secretion
of TGF -€X is a common characteristic of SCC cell lines, including the
A431 cell line and, which is of particular interest in the context of the
present study, one derived from an oesophageal tumour.
My results show that, under unstimulated serum-free conditions, the
A431, WHOO-I, -3 '1.. l-5 SCC cell lines constitutively secrete significant
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quantities of -o, over a period of 20 hours (see 'Iable lII). Such
secretion may be attributable to the mechanisms referred to in section
1.2.3.1 of Chapter 1. It is.important to note that the measured level of
sec-retedTGF-a may underestimate the endogenous production of this
ligand because it can exist, as noted in section 2.1.3, as a membrane-
bound biologically active precursor. Yoshida et al. (1990) have recently
demonstrated that certain oesophageal carcinoma cel1lines express as.
much as 38 to 60.2 picagrams per million cells of cell surface pro-TGF-a.
Table III Quantity ofTGF-a secreted in 20 hours under unstimulated
serum-free conditions
~.
Celllin~ No. cells' ng TGF.cx/rnl:t pg TGF-a!10'
cells"_,
A431 1.75xlO7 0.032 3.S
2.05xlC7 0.037 3.6
WHCO·l 1.96xl07 0.053 5.4
WHCO·3 5.53.:d06 0.024 8.6
-'.:::Sx10s 0.048 9.7
1.86xl07 0.078 8.4
r-" -
WHCO·5 9.80xl05 0.072 146,0
1 Conditioning ~Oml of DMEMlF12.
2 Radioimmunoaseay sensitivit, = 0.02ng TGF-a per tube.
3 Values are significant at pS;O.05 and represent the average of duplicate
determinations fr am a single experiment.
Expressed on a pg/l06 cell basis, the quantity of TGF-c secreted by
WHCO-5 in 20 hours is approximately 41 times that secreted by A4H1
cells over the same time period (present study) and some 5-1fJ times that
secreted by certain other cancel' ceI1lines in 48 hcurs (Derynek et al.,
1987; Smith et al., 1987; Kim et al., 1991). Although to the best ef my
knowledge no comprehensive survey of TGF-c secretion levels has been
published to date, it appears that the quantity of TGF-a secreted by
WHCO-5 cells under unstimulated serum-free conditions is relatively
high for a neoplastic cell line. The reason for this hs not known at
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present. Amplification of the TGF -n gene, enhanced expression and
stabilisation of its mRNA and unusually efficient cleavage of its protein
product could have played contributory roles; the first of these is
explored in Chapter 4. In contrast to most of the WHCO cell lines
reported on elsewhere, WHCO-5 has an unusually short doubling time
(approximately 20 hours; Prof. A..L. Thornley, personal communication).
The in vitro growth behaviour of this cell line may, at least in part, be
the result of a signalling defect involving overexpression ofTGF-a and
the EGF-R. It is possible, however, that this behaviour, compared with
that of the WHCO-! and -3 cell lines, is also partly attributable to a
relative dysfunction in the action of some factor, possibly 'rGF-13, that
inhibits cell growth in these cell lines. As mentioned in section 1.3.1 of
Chapter 1, TGF-j3 frequently has an important role in counterbalancing
the autocrine stimulatory effects ofTGF-a.
Cell lysate samples obtained from the subject cell lines were
electrophoresed on 10-20% gradient polyacrylamide gels and
electroeluteo to nitrocellulose sheets. The sheets were then subjected to
immunoprobe analyses, the results of which are shown in Figure 2.5.
In panel a of Figure 2.5, two distinct forms ofTGF-n were found to react
specifically with a sheep polyelonal anti-human TGF-a antiserum
(Biomedical Technologies Inc.), The lower molecular weight form
(approximately 21kd) is consistent with that reported in the literature
f01:' Oeglyeosylatad pro ..TGF -(X (Wong et al., 1989); the higher weight form
.pproximately 37kd) falls 'within the wide range recorded for
glycosylated meso-TGF-(X, species (Luetteke et al., If'''~8). The greater
intensity of the bands for WHCO-5 reflects the fact that this cell line
produces relatively more 'TGF-a.
Panel b of Fi~iJ.re 2.5 shows the results of immunoprobe analysis of
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lysates from the A431 and WHeO·s cell lines using a mouse monoclonal
anti-TGF-a antibody (Oncogene Science). The two higher molecular
weight species (34kd and 37kd) fall within the acceptable range for
differentially glycosylated meso-TGF-a (Luetteke et al., 1988; Van de
Vijver et al., 1991). It ir. conceivable, however, that the difference in the
meso-TGF-a molecular weights is partly attributable to differential
cleavage at the ala89-vaf)l) and lys9!'_lys97cleavage sites (Bringman et al.,
1987). The lower molecular weight species accord with forms ofpro-TGF-
a, the 21.4kd form being O-glycosylated 0Nonget al., 1989) and the 18kd
form lacking carbohydrate moieties (Teixido et al., 1990).
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.Figure 2.5 Biosynthesis and processing of TGF-a; under unstimulated serum-free
condttions, Panel a - Western immunoblot of cell lysate samples from A431 (lane 1),
Vl.THCO-l (lane 2), WHCO-3 (lane 3) and WHCO-5 (lane 4) ceils cultured for 20 hours under
unstimulated serum-free conditions. 'Iwenty five microlitres of lysaze sample (containing
approximately l.02xl04 cellsul) were loaded in each lane. The primary immunoprobe was
a highly specific polyclonal sheep antiserum raised against mature human TGF-a;
(Biomedical Technologies Inc.), Panel b - Western immunoblot of A431 (lane 1) and
WHGO-3 (lane 2) cell lysate samples (25~uper lane). The primary immunoprobe was a
mouse monoclonal antibody raised against recombinant human TGF-a (residues 33-50,
Oncogene Science). In both panels, the positions and molecular weights (kd) of the protein
standards are indicated on the left, and the weights of the immunoreactive TGF·a bauds
on the right.
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The upper molecular weight bands in Figure 2.5 are of particular
interest because they represent forms of TGF-a that have elsewhere
been found to be secreted (see, for example, Luetteke et al., 1988 and
Van de Vijver et al., 1991), but here are cell-associated. One possible
explanation is that meso-TGF-a may act in an autocrine mode, binding
to its receptor after short range diffusion. This speculation is not
precluded by the degradation of internalised ligand-receptor complexes
because, as shown by Ebner and Derynck (1991), a significant portion
ofinternalised TGF-a is recycled to the cell surface in undegraded form.
Further support for this speculati.on is pro rided by Van de Vijver et ale
(1991), who have shown that in A431 cells spec-hasofmeso-TGF-a of at
least 30kd become cell-associated via an autocrine pathway. My results
may also be explicable in terms of'intraerine stimulation, in which meso-
TGF-(\(.species art' generated intracelluJ.arly and ac~·on EGF-Rs in the
Golgi apparatus or endoplasmic reticulum (see Figure 1.1, Chapter 1).
Both intracrine and autocrine mechanisms may be operative: Van de
Vijver et al. (1991) assign a minor role to the former in A431 cells,
whereac Bringman I:.~tale (1987) ascribe a minor role to the latter in
transfected CHO cells,
2c8.2 Agent ..stimulated secretion ofTGF-a
Many studies, some of which are cited below, have shown that secretion
of TGF-a by normal and neoplastic cells may be enhanced above basal
levels following stimulation with specific agents. These include PMA,
serum factors, EGF and TGF -a. The purpose of this section is to report
on the efficacy of PMA, li'BS and EGF in promoting TGF -0; secretion in
the subject cel1lines.
PMA enhances the secretion of TGE'-a in cultured epidermal
38
keratinocytes (Pittelkow et al., 1989; Klein et al., 1992), in transfected
CHO cells (Pandiella and Massague 1991a and b), and in HT10S0
fibrosarcoma cells (Pandiella and Massague 1991a). My results
demonstrate that the secretion ofTGF-a; from A431 and WHCO-3 cells
is significantly and rapidly (within 15 minutes) elevated above basal
levels following exposure to 500nl\f PMA (see Figure 2.6).
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Figure 2.6 PMA-stimulatcd secretion of TGF-c:xunder serum-free conditions. a Total
TGF-c:xsecreted by unstimulated A431 cells in 20 hours, b total TGF-c:xsecreted by PMA-
stimulated A431 cells, e total TGF-c:xsecreted by unstimulated WHCO-3 cells:in 20 hours,
d total TGF-c:xsecreted by PMA-stimulated WHCO-3 (!JUs. F:M.Awas added to a final
concentration of 500nM 15 minutes prior to the end of the 20 hour conditioning period.
Secretion values are significant at p::;;0.05 and represent the average of duplicate
determinations from a single experiment.
At this concentration, PMA increases the rate ofTGF·a; secretion 3S-fold
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in A431 cells and 84-fold in WHCO-3 cells. Similar findings have been
reported in PMA-stimulated transfected CHO cells (Pandiella and
Massague, 1991a). The mechanism by which PMA enhances TGF-a
secretion in these cells may depend on PKC signalling, which has been
shown to be operative in transfeeted CHO celis (Pandiella and
Massague, 1991a). Although the activation of PKe can result in the
elevated expression of a variety of genes (Pittelkow et al., 1989;
Pandiella and Massague, 1991a), including the gene for TGF-a (Bjorge
et al., 1989; Anklesaria et al., 1990), the rapid nature of the observed
cleavage response suggests that this PKC-dependent mechanism does
not rely upon the relatively time-consuming synthesis ofpro-TGF-a but
rather upon activation of an essential cleavage enzyme, increased
exposure ofpro-TGF-a to this enzyme, or conversion ofpro-TGb"'l-ato a
better substrate for the enzyme.
FBS has been found to enhance the secretion ofTGF-a by a number of
human tumour cell lines (Derynck et a!0' 1987). In this study I have
demonstrated that the secretion ofTGF-a from A431 and WHCO-3 cells
is appreciably and quickly (within 15minutes) raised above basal levels
following exposure to 10% FBS ('iee Figure 2.7). Comparable findings
have recently been reported in serum-stimulated transfected CHO cells,
in which serum factors acutely activate pro-TGF-a cleavage via PKC-
dependent and -independent mechanisms (Pandiella and Maasague,
1991&and b). The cleavage-stimulating factor present in FBS is not a
protease and is probably of platelet origin (Pandiella and Massague,
1991b).
Finally, I consider the ability ofEGF to enhance the secretion ofTGFMa.
EGF stimulates the secretion of TGF-a protein in cultured epidermal
keratinocytes (Coffeyet al., 1987; Pittelkowet al., 1989) and in certain
melanoma and carcinoma cells (Singletary et al., 1990). It should be
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noted that in cultured epidermal keratinocytes TGF-a has been shown
to induce its own expression by means of an autoinductive mechanism
that presumably sustains and may amplify cellular responses to this
growth factor (Coffey et al., 1987). Here I show that a 20 hour exposure
to lOngiml EGF significantly and autoinductively increases the
accumulation of secreted TGF-a: in the media conditioned by A431,
WHCO-l, -3 and -5 cells (see Table IV).
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Figure 2.7 FBS-stimulated secretion QfTGF-a. a Total TGF-a secreted by unstimulated
A431 cella in 20 hours, b total TGF-a secreted by FBS-stimulated A431 cells, c total TGF-
C' secreted by unstimulated WHCO-3" cells in 20 hours, d total TGF-a secreted by FBS-
stimulated WHCO-3 cells. FBS was added to a final concentration of 10% 15 minutes prior
to the end of the 20 haul' conditioning period. Secretion values are significant at p~O.05
and represent the average of duplicate determinations from a single experiment.
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Table IV Quantity ofTGF-a secreted in 20 hours under EGF-
stimulated serum-free conditions.
I
I.. Enhane seme nt !
_ facto~
TGF-a secreted'In
presence of EGF2
Ceil line TGF-a secreted' in
absence of EGF
A431 12.5 3.6 2.5~';;;"""---+-'_;';"-------~~-----'.'------I
WHCO·l 6.4 5.4 0.2
WHCO-3 11.& 8.4~--------+---------------~---
WHCO·5 1448.6
0.4
146.0 8.9~------~_...,--------------~--------.....------~-------~
1 pg/106 cells.
2 lOng/mI.
3 Enhancement factor = (column 2-column 3)/column 3.
The enhancement ofTGF-a secretion is most pronounced in the case of
WHCO-5 cells. These results necessarily involve the relatively lengthy
process of EGF-enhanced TGF-a gene expression (Coffey et al., 1987;
Pittelkow et al., 1989) but also imply ; creased cleavage efficiency,
which may well be linked to PKC activation. As noted in section 1.3.2 of
Chapter 1, there is some evidence that autoinduction requires not only
lTIGF~Rtyrosine kinase activation but, also subsequent PKC signalling
triggered by the former (Pittelkow et al., 1989; Coffeyet al., 1992). The
triggering mechanism involves phosphorylation of phospholipase C-"6
(PLCuY)which, in turn, generates diacylglycerol (DAG)to activate PKe.
Thus: DAG, the endogenous activator of PKC, may operate to increase
cleavage efficiency in much the same way as the exogenous PKC
activator PMA.
Figure 2.8 shows the result of an immunoprobe analysis of A431 and
WHCO-:1whole cell lysate samples obtained from unstimulated cells and
from cells stimulated by various agents as specified in the legend.
Oncogene Science's mouse morn ,cj"'n31 antibody "was used as the primary
immunoprobe.
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Figure 2.8 Biosynthesis and processing of TGF-a in A431 and WHCO-3 cells under
unstimulated and stimulated conditions. Western immunoblot of cell lysate samples from
A431 cells - unstimulated (lane 1), PMA-stimulated (lane 2), FBS· stimulated (lane 3), EGF-
stimulated (lane 4); and from WHeO-3 cells -unstimulated (lane 5), PM:A-stimulated (lane
6), FBS-stimulated (lane 7), EGF-stimulated (lane 8). The concentration and duration of
application of the exogenous stimulatory agents are specified in section 2.2.2.1. Twenty five
microlitres of lysate sample (containing approximately 1.02xl04 cells per ;ll) were loaded
in each lane. The primary immunoprobe was Oncogene Science's mouse monoclonal anti-
human TGF-a antibody. 'TIle positions and molecular weights (kd) of the protein standards
are indicated on the left, and the weights (kd) of'the immunoreactive TGF-a bands on the
right.
The low and high molecular weight forms for WHCO-3 correspond to
glycosylated pro-TGF-a. and meso-TGF-a respectively, One would expect
the lower band of lane 5 to be more intense than those in lanes 6 and 7~
and less intense than that in lane 8; and the upper bands of lanes 6 to
8 to be more intense than that of lane 5. In both cases, however,
intensity appears to be independent of stimulation. The reasons for this,
lack of variation are not understood, but in the case of the upper bands
it may conceivably result from saturation of cell surface EGF·Rs by
meso-TGF-tXs.
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As regards A431, Figure 2.8 depicts high and low molecular weight
forms of TGF-a that are comparable with those of WHCO-3. No
variation in intensity is observable although the expected relative
intensities of the four lanes are the same as those in the preceding
paragraph. The lack of variation of intensity in the lower bands may
again be attributable to receptor saturation.
It is of interest to note that the presumed differential glycosylation of
unstimulated A13I cells (lane 1) also occurs following FBS stimulation
(lane 3) but only minimally after stimulation by PMA and EGF (lanes
2 and 4 respectively), suggesting that the latter pair of stimulatory
agents inhibit such glycosylation. As regards the lower molecular weight
forms ofmeso-TGF-c, the hypothesis of differential proteolytic cleavage
(section 2.3.1) would suggest that PMA and EGF, unlike FBS, may
favour cleavage at the lys98_Iys97 cleavage site.
2.8.8 In vitro effects of exogenous TGF...o.
Thus far in Chapter 2, it has been shown that the subject cell lines
constitutively produce and secrete varying quantities of TGF-a under
unstimulated serum-free conditions, and that secretion can be
significantly stimulated by various exogenous agents. As will be shown
in Chapter 3, they also overexpress the EGF-R. In the light of these
facts it is appropriate to consider the effects of exogenous mature TGF ...a
on the proliferation and migration of these cell lines in vitro.
Accordingly, cell proliferation and colony formation assays were
undertaken 011 the bases set out in section 2.2.4. The results are
discussed below.
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2.3.3.1 Cell proliferation assays
Graphs of the cell proliferation assays are presented in Figure 2.9. In
each panel, the lower horizontal line represents the mean number of
cells unexposed to exogenous TGF-a. The upper horizontal line
represents this mean plus one standard deviation (SD). The irregular
top line shows the trend of mean cell numbers as a function of
increasing concentration ofexogenous TGF-a; SDs ofplus one and minus
one are also indicated. In each case, the concentration of exogenous
TGF-u ranges from 0 to 100 ng/mI.
Panel a shows that the proliferation of A431 cells is stimulated above
the base level by exogenous TGF-a in the range of 0.1 to 10ng/mI, but
thereafter declines towards the base line. I am not aware of comparable
studies involving TGF-a, but the results reported for its homologue,
EGF, are naturally of interest. Cowley et al. (1984) have shown that,
under similar conditions, EGF in the range of 0.1 to 3.0ng/rol stimulates
the proliferation of A431 cells but thereafter progressively inhibits it to
levels that ultimately fall below control levels. This led them tv suggest
that, compared with normal keratinocytes, the observed responsiveness
of A431 cells to low levels of EGE' might be attributable to their
overexpression of EGF-Rs. Reiss et al. (1991) show progressive
enhancement ofDNA synthesis - and possibly, therefore, ofproliferation
- within the range they considered (i.e, 0 to lOng/ml). Noteworthy is
their caveat to the effect that the responsiveness of A431 cells to
exogenous EGF-R ligands is highly variable, possibly because of the use
of different sublines with distinct phenotypes.
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Figure 2.9 Cell proliferation assays. Panel at A431; panel b, WHCO-l. Cells were plated
out at a density of 5xlO" cells/well in 24 well plates in Iml DMEMtF12 plus 5% FBS.
Eighteen hours after this step, the medium was aspirated and 1ml of DMEM!.F12 was
added to each well. Twenty four hours later (day 0), the medium was removed and replaced
with O.5mllwell DME:M!F12 containing (J to 100 ng/m! TGF-tX.Viable cell numbers were
determined haemacytometrically on day 2 by trypan blue exclusion. Data, from a single
experiment, represent the mean of three to four points ± one SD.
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Figure 2.9 (continued) Cell proliferation assays. Panel e, WHCO-3; and panel d,
"-THeO-5. Cells were plated out at a density of 5x104 cells/well in 24 well plates in 1ml
DMEM!F12 plus 5% FBS. Eighteen hours afte'l this step, the medium was aspirated and
1ml of 1)ME1!1.F12was added to each well. Twenty four hours later (day 0), the medium
was removed and replaced with {).5mliwell DMEMlF12 containing 0 to 100 ng/ml TGF-Cl.
Viable cell numbers were det=rmined haemarytometrically on day 2 by trypan blue
exclusion. Data, from Iisingle experiment, represent the mean of three to four points ± one
SD.
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From panel b, it may be seen that the proliferation of WHCO·l cells
increases progressively with the addition of exogenous TGF-a to
approximately 2.4 times basal level at a TGF-a concentration of
lOOng/mI. In this connection, it is of interest to note that Chen et ale
(1991), in a study of the CE-48 human oesophageal sec cell line,
showed that the addition of exogenous TGF-('( resulted in a similarly
dose-dependent enhancement ofproliferation to 4.8 times the basal level
at a concent.ation of 600nglml.
The results for panel c show that the proliferation ofWHCO-3 cells is
moderately responsive to exogenous TGF·a in the rar ~geof 0 to O.lng/ml,
but thereafter is unaffected by increasing ligand concentration. A
possible explanation is advanced in the next section.
Finally, I consider the proliferative pattern of the WHCO>5 cell line. As
is apparent from panel d, proliferation is enhanced to a maximum level
of 2.4 fold at O.lng-/rnl and then progressively declines, closely
approaching the base level at lOOng/ml.Over the relevant range, the
pattern is similar to that reported by Stromberg et al. (1992) for the
OVCA420 ovarian carcinoma cell line. I would speculate that in the
VVHCO-5cell line the decline in proliferation from O.lng/ml onwards
may be attributable to increasing down-regulation and desensitisation
of the EGF-R. This speculation is consistent wit"..the fact that this cell
line secretes relatively high amounts of TGF-a. under unstimulated
serum-free conditions (see section 2.3.1) and that this secretion is
greatly augmented by exogenous EGF (see section 2.3.2).
2.8.8.2 Colony formation assays
The colony formation assays are depicted in Figure 2,10. 'I'he culture
dishes on the left hand (panel a) are controls that. show colony formation
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in the absence of exogenous TGF-a for the A431, WHCO-l, -3 and -5 cell
lines respectively; those on the right hand (panel b) show colony
formation in the corresponding cell lines in the presence of 10ng/ml of
exogenous TGF1-a.The number of colonies per culture dish is tabulated
in Table V.
Table V Colony formation assays - colonies per culture dish .
.
evUUne Number of colonies per Number of colonies per
dish (no TGF-a) dish (lOng/ml TGF-a)-
A431 281 124
WHCO-l 77 102
waco-a 215 ).14
WHCO·5 85 31
The first (horizontal) pail of dishes shows that in A43J eehs the addition
of exogenous TGF-a in serum-contan.ing medium .:nhibits colony
formation, a result that accords with the findings for this fell line by
Banks-Schlegel and Quintero (1986) in relation tc exogenous EGF, and
by Kumar and Mendelsohn (1990) in relation to exogenous TGF'··a.A
dmilar degree of inhibition is manifested in WHCO-5. In contrast, the,
addition of TGF-a to the WHeO-1 cell line promotes colony formation.
The reasons for this discrepant behaviour are not understood, but are
not surprising in the light of Veale and Thornley (1989). As noted in
their paper, there is no relationship between the biological response to
EGF) which is homologous to TGF~a, and the number ofEGF-Rs per cell
type, which is necessarily implicated in colony formation. Indeed,
variability of cell proliferation profiles appears to be the rule rather than
the exception (see, for example, Stromberg et al., 1992).
A431
WHCO-1
WHCQ-3
WHCO-5
49
a b
';'1,
... ~ ... ;" .; . : 1
: .. ~. '.. )411.... !: .
.,//
...._ .. .'. ,;
Figure 2.10 Colony formation assays. Cell lines are shown on the left. Panel a - no
exogenous TGF-a, panel b -10ng/ml exogenous TGF-a. Cells were plated out at a density
of 103 cells/dish in DMEMlFlL2 plus 5% FBS. Growth factor was added after colonies had
developed to a size of approximately 15 cells (day 0). Cells were fixed and colonies stained
on day 8.
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Inspection of the third pair of dishes, containing WHCO-3 cells, shows
that the right hand dish contains fewer (see Table V), but larger and
more diffuse, colonies than the left hand or control dish. This suggests
that the addition of 10ng/ml of exogenous 'fGF-a resulted in cell
migration and coalescence into larger colonies. Thus, the plateau
observed in panel c of Figure 2.9 may mean that, in the range of 0.1 to
100ng/ml, exogenous TGF-a sustains proliferation ofWHCO-3 cells by
promoting their migration.
It is appropriate at this point to comment on the mechanisms that link
proliferation and migration. In Barrandon and Green (1987), it has been
shown that the growth of an epidermal keratinocyte colony depends on
outward migration of proliferating cells at the colony perimeter. Such
growth is sustained by exogenous EGF and TGF-o, in the absence of
which the rate of cell migration becomes a limiting factor and cells in
the interior of the colony tend to leave the basal layer and terminally
differentiate. EGF has been shown to stimulate migration in a number
of normal and neoplastic cells. This effect, which is important for the
maintenance of proliferative potential in normal keratinocytes and for
the process of wound healing, is brought about by alteration in the
expression ofcertain cytoskeletal and secretory protein genes. Migratory
cells are characterised by an undifferentiated phenotype (Nickoloff'er al.,
1988). In an earlier study of the WHCO-3 cell line, I have shown that
the cytoskeletons ofmigratory cells are less differentiated than those of
their non-migratory counterparts. The cytoskeletal profiles of the
migratory cells were found to exhibit enhanced actin production, a
reduction in high molecular weight type 1 and 2 keratins, and an
accumulation of certain lower molecular weight type 1 forms (Jones,
1989). These results were achieved by the addition of 10ng/ml of
exogenous EGF. Given the homology between 'rGF-a and EG~"',the
migratory response, ofWHCO-3 cells to 10ng/mI of exogenous TGF-a.
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observed in the present study is not at all surprising.
Migration requires not only changes in cytoskeletal architecture, but
also the production and secretion of enzymes that facilitate cell motility
by degrading components of the extracellular matrix. In a study of
human epidermal raft cultures, Turksen et al. (1991) have shown that
TGF-c, in addition to enhancing proliferation, promotes ke:ratinocyte
migration by stimulating the production and secretion of type 1
collagenase and gelatinase. Highly germane to this study is their
conclusion that, in view of the connection between cell migration and
tumour stastasis, TGF-a may have an important role in sees and
tumour invasion.
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Chapter 3
The Epidermal Growth Factor Jl~ct"ptor
3.1 Introduction
8.1.1 Receptor structure and function
'I'he EGF-R is a 170kd protein composed of a single glycosylated
polypeptide chain of 1186 amino acid residues (Carpenter and Cohen,
1990). The receptor belongs to a group of structurally and functionally
related cell surface proteins that possesses an intrinsic tyrosine kinase
activity (Canals, 1992). As noted in Kearsley et al. (1991), the EGF-R is
markedly homologous to the transforming protein of the avian
erythroblastosis v-erbB oncogene and to that of c-erbB2, the human
equivalent of a rat neuroblastoma oncogene product designated neu.
According to Nair et al. (1992), the receptor consists of four functional
domains: an extracellular ligand-binding domain, a short
transmembrane domain, a tyrosine kinase domain, and a carboxyl
terminal domain (see Figure 3.1).
3.1.1.1 The extracellular ligand-binding domain
This domain comprises four subdomains and is characterised by its
ability to bind to six structurally related ligands: namely, EGF, TGF-a,
vaccinia virus growth factor, myxoma virus growth factor, Shope fibroma
virus growth factor, and amphiregulin (Korcet al., 1991). Subdomain III,
which is flanked by the cystine-rich subdomains II and Iv, contains
major structural determinants that are important in ligand binding
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(Ullrich and Schlessinger, 19!:lO;Avivi et al., 1991). Ligand-binding
stimulates the receptor's tyrosine kinase domain, resulting in the
phosphorylation of the receptor itself and a number of cytoplasmic
substrates germane to the receptor's signal transduction mechanism
(Decker et al., 1992). These substrates, which include PLC-yv the
GTPase activating protein of ras (GAP)and raf-1 kinase, are described
in Carpenter and Cohen (1990)~together with a putative signalling
mechanism.
Extracellular IIg&nd-blndlng domain
(residues 1-621)
Tranamembrane domain
{residues 622-644)
tyrUS:iiCt Iflnase domain
(residues 700-QGet
CarboxyH,grmlnal domain
lresldu&s 9S7-1186)
8
•I
Figul'~ 3.1 Salient features of the EGF-R (adapted from Carpenter and Cohen, 1990; and
Ullrich and Schlessinger, 1990). Dotted boxes represent cystine-rich subdomains of the
extracellular ligand-binding domain; asterisk and open circle represent threonine residue
654 and serine residue 1046/7 respectively; filled circles represent sites of tyrosine
autophosphorylation,
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Although the extracellular ligand-binding domain is generally considered
to be indispensable for receptor dimerisation and hence for tyrosine
kinase activity (Ullrich and Schlessinger, 1990; Canals, 1992), a study
by Kwatra et al. (1992) has shown that EGF-Rs that lack their
extracellular Iiga. .d-binding domains are still capable of dimerising.
3.1.1.2 The transmembrane domain
It is generally accepted that this alpha-helical domain does not directly
influence signal transduction but is instead a passive anchor of the
recepto:r. to the membrane (Aaronsox, 1991). However, a point mutation
within tile transmembrane domain of neu enhances its transforming
properties (Ullrich and Schlessinger, 1990). Moreover, as noted in Qian
et al. (1992), it may be th« transmembrane domain that mediates EGF-R
dimerisation.
3.1.1.3 The tyrosine kinase domain
This highly conserved domai.n comprises an KIP-binding site, an enzyme
catalytic site and several regulatory sites (Ullrich and Schlessinger,
1950). The way in which ligand-binding to the extracellular domain
activates the domain's catalytic site is not yet fully understood (Sorkin
and Carpenter, 1991). As noted in Canals (1992), two different
explanatory models have been proposed and are still in contention.
According to the intramolecular model of Koland and Cerione (1988),
ligand-binding induces an intramolecular conformational change which
is propagated across the transmembrane domain and results in direct
activation of the tyrosine kinase activity The alternative, intermolecular
model of Schlessinger (1988) proposes that ligand-binding shifts a
hypothetical equilibrium between inactive monomeric receptors and
active dimeric forms towards the latter because of the higher affinity of
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the ligand for the dimer, Activation ,..C the tyrosine kinase results from
interactions between subunits within the receptor dimer. Despite the
arguments in favour of the intramolecular model in Carraway and
Cerlone (1991), the balance of experimental evidence seems to favour the
intermolecular model (Canals, 1992).
The phosphoryl transfer activity of the catalytic site results in
phosphorylation of the receptor :tself, a process termed
autophosphorylation. It also causes the phosphorylation of a number of
specific cytoplasmic substrates, including PLC-'Yl(Meisenhelder et al.,
1989; Rotin et al., 1992), GAP (Liu and Pawson, 1991), raf-l kinase
(Baccarini ei al., 1991), and many cytoskeletal components (van Bergen
en Henegouwen et al., 1992). Tyrosine phosphorylation modifies the
functien of these proteins and t.....ereby initiates several biochemical
events that ultimately lead to DNA replication and cell division (Magro
et al., 1991). According to Mooibroek et al. (1992), the activity of the
catalytic site is also required for the process of ligand-induced receptor
endocytosis.
3.1.1.4 The carboxyl terminal domain
Five residues for tyrosine phosphorylation are located within this
domain (Vega et al., 1992). In their non-phosphorylated state, these
residues define an autoinhibitory region (Walton et al., J "90; Sorkin et
al., 1991) that competes with receptor substrates for the tyrosine
phosphorylating activity of the tyrosine kinase domain (Helin and
Beguinot, 1991). According to Countaway ei al. (1992), phosphorylation
of serine residue 1046/7 acts as a negative regulator of kinase activity.
There is evidence for a close association between the deletion of this
serine residue and increased sarcomagenic potential of the v-erbB
oncogene product. The tyrosine phosphorylated carboxyl terminal
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domain determines the kinase's substrate specificity by preferentially
binding to the conserved non-catalytic src homology domains of receptor
substrates such as PLC-'Yl and GAP (Rotin et al., 1992; Vega et al.,
1992). The carboxyl terminal domain also plays an important role in the
processes of receptor endocytosis and degradation (Decker et al., 1992;
Wedegaertner a.id Gill, 1992). Recent evidence suggests that this
domain may also be important in the process of receptor dimerisation
(Kw..tra et al., 1992).
3.1.2 Deseneitieation of kinase activity
Desensitisation of the EGF-R's tyrosine kinase activity provides an
important physiological control over the receptor's signal transduction
(Countaway et al., 1992). Receptor desensitisation may be achieved in
one of'twoways: by signal attenuation following receptor internalisation
and degradation (Cadena and Gill, 1992); or by phosphorylation of
negatively regulatory receptor threonine and serine residues by non-
receptor kinases (Countawayet al., 1992j. Inthe latter, the non-receptor
kinases are indirectly stimulated by ligand-binding to the EGF·R and,
in a positive feedback loop, utilise the receptor as one of their substrates
(Carpenter and Cohen, 1990). Examples in which receptor
desensitisation is mediated by these kinases include phosphorylation of
threonine residue 654 by PKC and of serine residue 104617 by CAM II
kinase (Countawayet al., 1992). 'I'hese enzymes do not act by reducing
EGF-R dimerisation but may directly alter the receptor's conformation
or indirectly alter the receptor's interaction with its cytoplasmic
substrates.
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B.l~3 7Wo classes of receptor exist
Although the EG~'-R is a single gene product (Gladhaug et al., 1992)
that exhibits no heterogeneity in primary structure (van Belzen ei al.,
1991)t two distinct classes have been identified: a major class of low-
affinity receptors and a minor class of high-affinity receptors (Berkers
et a; 1992).
At present there is no coherent and generally accepted explanation for
this observed difference in ligand-binding affinity. According to the
proponents of the intermolecular model of tyrosine kinase activation,
high-affinity receptors exist as dimers that arise following ligand-
induced association of low-affinity monomeric forms (Carraway and
Cerione, 1991). This theory is not absolutely valid, however, because
there is evidence far the existence of high-affinity monomers (De Fize et
al., 1989). Other research .....rs therefore favour the proposal that
attainment of the high-affinity state is related to ligand-induced
association of EGF-its with cytoskeletal elements (van Belzen et al.,
1991; van Bergen en Henegouwen et al., 1992). Neither theory is
consistent with the fact that high-affinity receptors must theoretically
exist prior to ligand-binding (Ballot et al., 1990). The recent
demonstration that EGF-Rs are capable of dimerising in the absence of
ligand-binding (Kwatra et al., 1992) lends partial support to the view
that receptor dimerisation may generate the high-affinity state, but fails
to explain the existence of high-affinity monomers.
'I'he functional significance of the two classes ofEGF~R is also unelear
at present. Activation of the high-affinity class may be the primary
means by which EGF stimulates cells (De Fize et al., 1989), although a
role for the low-affinity class in EGF's signal transduction cannot be
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excluded (Bellot et al., 199U\ Gladhaug et al., 1992). Of particular
relevance to the present study is the suggestion that TGF-c nsay be
primarily dependent on the low-affinity receptor class for eFciting its
mitogenic effect (Cutry er al., 1988).
8.1.4 The EGF-R is often ooerexpressed in
neoplastic cells
According to Cadena and Gill (1992), the most frequent abnormality
observed in human neoplasms is the increased production of certain
receptor tyrosine kinases. As noted in Veale and Thornley (1989), the
first reports concerning EGF-R overproduction resulted from studies on
the A431 epidermoid carcinoma cell line in 1977. Recent laboratory and
clinical data suggest that many other cancer cell lines and primary
human neoplasms exhibit unusually high levels ofEGF-R, and that this
abnormality is concomitant with rapid cellular proliferation and poor
patient prognosis (Pollak et al., 1991). Recent ~~search by Barton et al.
(199) and Lemoine et al. (1992), for example, has strongly correlated
the poor clinical prognosis associated with pancreatic adenocarcinoma
with autocrine growth stimulatory mechanisms involving supemumary
EGF-Rs. Overexpression of the EGF-R is widely regarded as a hallmark
of SCCs (Ozanne et al., 1986); and is found in, inter alia, these of the
cervix (Maruo et al., 1992), oral region (Kawamoto et al., li;.:......:.)and
oesophagus (Ozawa et al., 1987; Reiss et al., 1991). In the latter, such
overexpression serves as a significant prognostic indicator (Ozawa et al.,
1989).
A substantial increase in the number ofEGF-Rs may serve to promote
abnormal cellular proliferation in various ways. According to Gerwin
(1992), receptor overexpression may increase the probability of receptor
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oligomerisation, or it may allow a cell to escape interference from
negative signalling pathways. Inaddition, the presence oflarge numbers
of EGF-Rs may amplify the mitogenic effect of exogenous ligand
(Theodorescu et al., 1991) and provide hypersensitivity to Jaw
concentrations of mitogen (Pollak et al., 1991). Furthermore, the
production of supernumary receptors may reduce the ability of receptor
endocytosis and degradation to attenuate the mitogenic signal (Masui et
al., 1991; Cadena and Gin, 1992).
3.1.5 Aim of" «pter 3
As described in detail in Chapter 2, the WHCO-5 cell line secretes
relatively high Ievels of TGF-a under unstimulated serum-free
conditions. It has been proposed that this cell line's unusually short
doubling time .may be partly the result of a signalling defect involving
overexpression ofTGF-a and low-affinity EGF-Rs (Thornley and Jones,
1992). Accordingly, the aim of the experiments reported on in this
Chapter is to determine the number and affinity ofEGF-Rs in WHCO-5
ceR~ by means of the 125I_EGFcompetitive binding assay of Veale anu
Thornley (1989). The \\THCO-3 cell line, which has been shown in this
assay to produce superoumary low-affinity EGF-Rs, WdS used to control
for experimental methodology. The well-studied A431 cell line was used
for positive control purposes.
3.2 Materials and Methods
8.2.1 1251;'EGF competitive binding assays
125I_EGF competitive binding assays were performed according to the
method described in Veale and Thornley (1989) with minor
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modifications. Approximately 1.5xl05 cells per well were plated out in
DME~lfF12 plus 5%FBS into 24 well tissue culture plates (Nunc). After
24 hours the cells were washed twice with 0.5ml!well ofbinding medium
(DMEMlF12 plus 0.1% bovine serum albumin (BDH Chemicals)) and
incubated at 37°Cin a humid atmosphere of 5% CO2 and 95% air for 30
minutes. The cells were then re-incubated in fresh binding medium for
45 minutes at 4"C. After aspiration of the medium, approximately 300
Ill/well of fresh binding medium, contain! 19 0.84 - 0.89 ng/ml of 1251_
human EGF (specific activity of 180.98 JiCiJ g,Amersham) plus 0 - 21.86
ng/ml of unlabelled receptor grade EGF (Sigma), was added in triplicate
to the wells. Non-specific binding was measured in the presence of a
lOOD-foldexcess of unlabelled receptor grade EGF; the values appear in
Appendix B. After incubation at 4 ·Ccfor 3 hours, the cell monolayers
were washed four times with ice-coldbinding medium and solubilised in
0.5m11we1l1MNaOH for 1 hour at 37°C. 125I-EGF binding assays were
conducted at 4"C for a period of3 hours because steady state binding of
EGF is known to be attained in the subject cell lines under these
conditions (Massague, 1983; Veale and Thornley, 1989). Finally, the
solubilized cells were transferred to 12x75-mm plastic tubes and the
radioactivity was determined using a Packard Cobra auto-gamma
counter. The number of cells per well was ascertained
haemoeytometrieally by trypan blue exclusion.
3.2.2 Scaichard analysis
EGF-R nU1:~l,t·i' and affinity were determined from the 1251-EGF
competitive binding data by Scatchard analysis, using the LIGAND
computer programme of Munson and Rodbard (1980). This programme
is an iterative procedure for the best fit of two independent binding sites
(Wang et al., 1992) and, according to Veale and Thornley (1989), is
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based on a statistically valid curve-fitting algorithm.
3..3 Results and Discussion
3.3.1 EGF-R expression in the A431, WHvO-3 and
..5 cell lines
~431 cells are known to express an unusually high number ofEGF-Rs
011 their cell surfaces (Ihara et al., 1991). As noted in section 4.1.4 of
Chapter 4, this overproduction is the result of an amplification of the
receptor gene sequence. In some studies both high- and low-affinity
receptor classes have been identified (De Fize et al., .L989), but other
studies have failed to detect the high-affinity class, and report only the
presence of supernumary low-affinity receptors (Chen et al., 1991). The
reason for this discrepancy has not been addressed in the literature but
it may be ascribable to the use of -henotypically different sublines. The
WHCO-3 cell line is known to produce exceptionally high numbers of
low-affinity EGF-Rs, This may be a result of direct xenotransplantation
from the original tumour biopsy (Veale and Thornley, 1989) but, as
discussed in Chapter 4, may well be attributable to EGF-R gene
amplification.
The '25I-EGF competitive binding data obtained in the present study for
the A431, WHCO-3 and -5 cell lines is summarised in Appendix B (see
Tables B1, B2 and B3 respectively). Seatchard analysis of this data
produced linear plots that are typical of those obtained in studies of
systems comprising single affinity ligand-binding sites (see Figure 3.2),
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Figure 3.2 Scatchard analysis (1f 125I-EGFbinding for the A431 and WHCO-3 ce111ines.
The l~.5I_EGFbinding assays were performed at 4'C 1;\S described in section 3.2.1. Each data
point represents the average of triplicate determinations from a single experiment. The
ordinate mdicates the ratio of bound to free (BIF) 125I-EGFand the abscissa indicates the
molar concentration of bound EGF per lOll cells,
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Figurs 3.2 (continued) Scatchard analysis of 125I-EGI<'binding for the \V'HCO-5('"n line.
The lz~I-EGF binding assays were performed at 4·C as described ill section 3.2.1. Ee,(...l data
point represents the average of triplicate determinations from a single experiment. The
ordinate indicates the ratio of bound to free (ElF) t2GI-EGF and the abscissa indicates the
molar concentration of bound EGF per 105 cells.
Calculation of the number of receptors per cell and the receptors'
dissociation constants for the A431 and WHCO-3 cell lines produced
values that are in good agreement with those reported in the literature
(see Table VI).
Although the dissociation constant calculated for the WHCO-3 cell line
is somewhat smaller than that reported previously, its magnitude is
compatible with those given for EGF-Rs that are considered to belong to
the low-affinity receptor class (van Belzen et al., 1991; Gladhaug et al.,
19~2;Hongo et al., 1992).Scatchard analysis of the 125I_EGFcompetitive
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binding data for the WHCO-5 cells showed that they express 6.4xl06
low-affinity EGF-Rs per cell, a figure which is approximately 12 times
higher than the corresponding figure for normal oesophageal
keratinocytes (see Table VI).
Table VI Number of EGF receptors per cell and dissociation
constants
r--
Cell line Dissociation Number of Reference
cODStant~) receptors per cell
Normal 4.2xlO·9M 5.5xl0' Veale and Tho:mley, 1989
oesophageal
keratinocytes
A431 1.4x10·~ 2.8x10B present study
1.lxl0·"M: 2.5x10' Chen et al., 1991
WHCO.1 2.2x10·9M 4.2xlOB Veale and Thornley, 1989-,
WHC0-3 6.2xlO'l~ 12.9x1011 present study
1.1xlO·'M lO.4xlO' Veale and Thornley, 1989
WHCO.5 4.2lClO·1CIM 6.4xlo' present stt'Lly----
Each analysis in the present study consisted of 8 to 9 different unlabelled EGF
concentrations performed In triplicate. The number of receptors per cell and dissociation
constants were calculated from 125I-EGF binding data using the LIGAND computer
programme of Munson and Rodbard (198(1). Cell numbers were determined
haemocytometrically by trypan blue exclusion.
As discussed in Chapter 2, the WHCO-5 ~(:!nline secretes relatively high
levels of TGF ..a, under unsti.aulated serum-free conditions. It has been
proposed that the rapid in vitro growth characteristics of this cell line
may partly be the result of an autocrine signalling defect im "lving
overexpression of'rGF-a and low-affinity EGF'-Rs (Thornley and Jones,
1992). The present demonstration of supernumary low-affinity EGF~Rs
on the surface of these cells lends experimental support to this proposal.
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3.8.2 EGF..R ouerexpression and neoplastic
transformation
There is persuasive experimental evidence to support a positive role for
EGF -R overexnression in the processes of cellular transformation in vitro
and tumourigenesis itt vivo. Overexpression of EGF-Rs in NIH 3T3
fibroblasts following transfection with a human EGF -R eDNA expression
vector results in ligand-dependent transformation in vitro (Di Fiore et
l., 1987; Riedel et ca., 1988). Recent work by Masui et al, (1991) has
shown that lipofection ofNR6 3T3-derived cells with a wild-type EGF-R
expression vector produces cells th?t. are slightly tumuurigenic in
athymic mice; and that lipofection of NR6 cells with a mutant EGF-R
sequence encoding receptors that are incapable of being down-regulated
results in significantly enhanced tumourigenicity in vivo.
Neuplastic transformation in vivo is a multi-ntep process: firstly, the
normally interdependent systems controlling proliferation and
differentiation must be uncoupled; secondly, proliferation must be
stimulated in such a way as to result in extensive division of the
transformed cells (Cross and Dexter, 1991). It is unclear whether EGF-R
overexpression has a primary causative role in this process or merely
acts to maintain or enhance it. In the aforementioned studies ofDi Fiore
et al. (1987) and Riedel et al. (1988), it is claimed that such
overexpression, coupled with the unmasking effects of'ligand binding, is
a sufficient cause of transformation in NIH 3T3 mouse fibroblasts. It
mnst be noted, however, that their in vitro studies focused on cells that
were already immortalised; and that, as regards in. vivo systems, the
authors considered their findings to be suggestive rather than
conclusive, According to Pollak et ul, (1991), the expression of excessive
numbers ofEGF-Rs is more likely to contribute to the progression of
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neoplastic transformation rather than to cause its initiation. Extensive
clinical evidence strongly supports the role of excessive EGF-R signalling
in the progression of many types of human cancers (Redemann et al.,
1992). Autocrine activation of overexpressed EGF-Rs may promote
progression by conferring a selective growth advantage on an already
aberrant preneoplastic cell (Hollstein et al., 1988). The role of the EGF-R
in maintaining the tumourigenic properties of cancer cells is well
illustrated by the ability of specific neutralising antibodies that bind to
the EGF-R to reduce the proliferation of secs in vitro (Reiss et al.,
1991) and to suppress the tumourigenicity of EGF-R-transfected NRS
cel1~ in vivo (Masui et al., 1991).
8.3.3 The EGF..R and oesophageal cancer
For the purposes of the present study, it should be noted that the
question whether EGF-R overexpression, coupled with ligand-binding,
has a primary or a secondary role in carcinogenesis is not of the essence.
What. is important is the undeniable fact that it is clearly implicated, at
least by virtue of the growth advantage it confers, in the multi-step
process of neoplasia.
A link between neoplasia and the hyperproduction ofEGF-Rs has been
demonstrated in many different cell types since it was first reported ill
connection with A431 cells in 1977. Such overexpression has been
described as the hallmark of sees (Ozanne et al., 1986). Regarding
human oesophageal secs, although there are examples characterised by
a relatively low number of high-affinity receptors (Banks-Schlegel and
Quintero, 1986), there is considerable evidence to suiport a positive
correlation between this type of cancer and the production of'
supernumary low-affinity EGF-Rs. Such overexpression has recently
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been noted in a number of established oesophageal SCC cell lines (Veale
and Thornley, 1989; Yoshida et al., 1990; Chen et al., 1991). The results
of the present study in respect of the WHCO-3 and -5 cell lines confirm
and extend those reported in Veale and Thornley (1989). A functional
role for overexpressed EGF-Rs in vivo is clearly suggested by the
demonstration of excessive levels ofEGP -RmRNA and protein in several
primary oesophageal secs (Ozawa et al., 1987; Hollstein et al., 1988).
From Table VI it may be deduced that the VlHCO-l, -3 and -5 cell lines
produce between 8 and 23 times as many lew-affinity cell surface EGF-
Rs as do normal oesophageal keratinocytes. As shown in Chapter 2,
these cell lines secrete significant quantities of TGF-a under
unstimulated serum-free conditions. Hyperproduction of low-affinity
EGF-Rs is significant in view of the fact that TGF-a may be primarily
dependent on this class ofEGF-R for eliciting its mitogenic signal (Cutry
et al., 1988). Taken together, my results support the speculation, which
will be elaborated in Chapter 5, that TGF-a; and the EGF-R act in an
autocrine mode to regulate the in vitro growth behaviour of these cell
lines.
As mentioned in section 3.1.4, overexpression enhances abnormal
proliferation in various ways. One such way is the promotion of receptor
oligcmerisation. A second is the reduction of interference by negative
signalling pathways that would otherwise desensitise the EGF-R
tyrosine kinase activity by phosphorylating negative regulatory residues
in the receptor's intracellular region. Thirdly, the presence of excess
receptors may provide hypersensitivity to mitogenic stimulation. Finally,
receptor hyperproduction may result in the reduced ability of receptor
endocytosis and degradation to attenuate the mitogenic signal.
There remains for consideration the important question of what causes
..._ ;.,
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EGF-R hyperproduetion. This forms part of the subject- matter of the
next Chapter.
f',,-; ..
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Chapter 4
Gene Amplification
4.1 Introduction
4.1.1 Cancer and genetic instability
There is compelling evidence that cancer is a process that involves
multiple genetic lesions (Hunter, 1991). These lesions, whether initiating
or progression-associated events, may be mediated through gross
chromosomal changes and thus be cytogenetically visible. The common
tumour chromosome aberrations fall into two broad classes: structural
and numerical. The former includes translocations, inversions, deletions
and amplifications; the latter comprises losses or duplications of entire
chromosomes (Solomon et al., 1991).
As discussed in section 1.2.2 of Chapter 1, two classes of genes are
implicated in cancer. First, there are the proto-oncogenes, which can be
converted from normal cellular genes to oncogenes by a variety of
submicroscopic events including point mutations, small insertions and
deletions, and juxtaposition to other chromosome sequences.
Juxtaposition can be visualised cytogenetically as a translocation 01'
inversion. At least three oncogenes - myc, rel and abl - are known to
result from structural rearrangement of proto-oncogenes. The second
type comprises the tumour suppressor genes, which, in contrast to
oncogenes, contribute to oncogenicity through their loss rather than
their activation. Their behaviour is recessive, and both copies must be
inactivated for tumour formation to occur. In general, structural
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rearrangements that consistently juxtapose two different chromosomal
regions are considered to contain dominant oncogenic sequences;
deletions or monosomies are thought to be the site of recessive tumour
suppressor genes {Solomonet al., 1991).
Oncogenes are often found to t·, amplified in advanced tumours,
presumably because their overexpression through amplification confers
a selective growth advantage (Stark et al., 1989). The present Chapter
is concerned with a pvcsible role for amplification _ the TGF-a; and
EGF-R genes in the cell lines that form the basis of this study.
4.1.2 Manifestations and stages of gene
amplification
Since its discovery in drug-resistant eukaryotic cells, somatic
amplification of specific genes has been implicated in an increasing
variety of the adaptive responses of cells to environmental stresses
(Alitalo and Schwab, 1986).
According to Stark et al. (1989), amplified DNA can often be observed by
light microscopy either as an extended chromosomal region (ECR) or as
extrachromosomal elements called double minute chromosomes (DMs).
Extrachromosomal elements play an important role in amplification, and
it now seems likely that their formation is coupled to chromosomal
deletions and perhaps to other chromosomal abnormalities such as
inversion, translocation and possibly even chromosome loss.
Amplifications are selected in vitro in distinct steps of increasing drug
concentration (Stark et al., 1989). The primary event of amplification
takes place in a single cell and thus has not been amenable to direct
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study so far. Secondary events, not necessarily selected for by the drug,
may then follow during growth to a clonal population sufficiently large
for analysis. If tl;e amplified DNAis extrachromosomal in this first-step
clonal population, increasing the drug concentration ina second step will
simply select cells with more of the same element. If the amplified DNA
is intrachromosomal, however, a second and distinct amplification event,
again taking place in a single cell, is required to generate the additional
copies of the target gene for survival.
As noted by Stark et al, (1989), it is unclear whether DMs and ECRs
represent different outcomes of the same primary event or arise from
fundamentally different processes. DMs can integrate to generate ECRs
at random chromosomal locations, whereas ECRs are sometimes found
at the native locus. During amplification, DNA sequences from different
parts of the genome are joined together to form novel structures. Most
of the amplified DNA is represented by a single rearranged structure
that is formed at an early stage of the process and subsequently
reamplified. The preferential nature of the process suggests that the
rearrangement of DNA creates or brings close to the selected gene
certain sequences that act in cis to favour amplification.
4.1.3 Mechanisms of gene amplification
As noted by AIitalo and Schwab (1986), there is evidence that
illegitimate DNA replication occurs to a limited extent in normal cells.
In unselective conditions this DNA is probably lost, perhaps via the
formation ofmicronuclei. However, if there is selective pressure to retain
an increased gene dosage then a progressive multiplication of gene copy
number ensues.
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The incidence of cells bearing amplified genes under conditions of
cytotoxic selection can vary by two orders of magnitude and is greatly
increased by the presence of mitogenic substances. But what causes
amplification? One putative mechanism is provided by the so called
"onion-skin" model depicted in Figure 4.1.
ORIGIN
REPLICA nON
RECOMSINA ilON
ECR~
Figure 4.1 "Onion-skin" model of DNA arnplification in tumour cells. The m denotes a
hypothetical (onco)gene within the amplified domain. An explained in section 4.1.3,
unscheduled replication of DNA results inmulticopies that must be resolved during the
cell cycle into DMs or ECRs.
The following explanation of the model is drawn from Alitalo and
Schwab (1986). In the top part of the Figure, chromosomal DNA is
replicated bidirectionally from a fixed site of origin during the S phase
of the cell cycle.With a certain probability, unscheduled replications of
the already replicated DNA may occur during a single cell cycle, leading
to a structure shown as superimposed replication bubbles, The multiple
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copies of DNA must resolve into a linear arr 'y before the next mitosis.
This can occur by hom ""Yogous or illegitimate recombinations between
different amplified segments, The process can l~ad to a linear, tandem
but heterogenous multicopy unit, shown on the IE:;li which may in some
cases evolve into an ECR. If suitable recombinations occur,
extrachron .nal circular DNA elements containing origins for DNA
replication are formed, which may be '(::e precursors of DMs. ?he In
denotes a hypothetical (onco)gene within the amplified domain.
It should be noted, however, that no clear-cut cause of amplification has
been established wild that several rival theories still compete to explain
its mechanisms (Bishop, 1991). These theories fail into two classes: in
the one, over-replication within a single cell cycle is responsible for
generating the extra copies of DNA; in the other, unequal segreg-xtion
is involved and the control of replication within each cell cycle is normal.
Five possible models are described in Stark et al. (1989).
4.1.4 Tumour speci, .,.;Jity of'oncogene amplification
The transition of proto-oncogenes to oncogenes through some form of
genetic damage seems to have a specific or patterned association with
different kinds of human malignancies, as shown in Table VII from
Bishop (1991).
EG~'-R gene amplification has been found in several tumours, including
gliomas and secs (Wood et al., 1992). By far the most commonly
amplified gene iii gliomas, particularly glioblastomas, is that encodig the
EGF-R (Torp et al., 1991; Fuller and Bigner, 1992). The EGF-R gene is
rearranged in a significant percentage (if gliomas in which it is
amplified, resulting in extracellular domain deletions that yield
74
truncated EGF·Rs (Humphreyet al., 1991). Furuta et ala (1992) also
observe that overexpression of the EGF-R in certain other human
tumours, particularly secs, is the result of receptor ge: amplification.
It may be necessary, however, to distinguish between results obtained
from primary tumours and those from cell lines derived from such
tumours. Thus, Yamamoto et ala(1986) found EGF-R gene amplification
in only one out of six primary sec tumours but in ten out of twelve SCC
cell lines, of which three out of five were oerophageal, The incidence of
amplification has also been found to be relatively low inprimary secs
of the head and neck (EI-Zayat et al., 1991; Kearsleyet al., 1991), the
nasal cavity and paranasal sinuses (Furuta et al., 1992), and the
oesophagus (Hollstein et al., 1988).
Of particular relevance to the present study .s the research that has
been conducted on the A431 cell line and several oesophageal secs.
Overexpression of the EGF-R in A431 cells is principally the result of
receptor gene amplification and mRNA hyperproduction (Lin et al.,
1984). In these cells, the receptor gene is also known to be translocated
and rearranged (UHrich et al., 1984). As regards oesophageal secs,
amplification of the EGF-R gene has, been reported both in tumour-
derived cell lines (Ylamamoto et al ; H~86; Yoshida et al., 1990) and in
primary tumour samples (Lu et al. 1988; Hollstein et al., 1988),
although the frequency of amplif aation in the latter is relatively low
(Hollstein et al., 1988). On the other hand, amplification of the TG~"-a.
gene has not been detected in oesophageal SCC cell lines (Yoshida et al.,
1990) and appears te be a rare event, the only reference known to me
being Barrett-Lee et al, (1990) concerning an isolated mammary
dysplasia.
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Table VII Proto-oncogenes and human tumours: some consistent
associations,
Proto-oncogene Neoplasmfs) Lesion
abl Chronic myelogenous translocation
leukemia
EGF-R (erbB-l) Squamous cel~cinoma; astrocytoma amplification
neu (erbB-2) Adenocarcinoma of breast, ovary and stomach amplification
gip Carcinoma of ovary and adrenal gland point mutations
gsp Adenoma of pitiutary gland; Carcinoma of point mutations
thyroid
myc Burkitt's lymphoma translocation
Carcinoma of lung, breast and cervix amnhfication
- -
L-myc Carcinoma of lung amplification
N-myc Neuroblastoma; Small cell lung carcinoma amplification
H·ras Carcinoma of colon, lung and pancreas; point mutations
Melanoma
K-ras Acute myelogenous and lymphoblastic point mutations
l~emia; Carcinoma of thyroid; Melanoma -
N-ras Car-cinoma of genitourinary tract and thyroid; point mutations
Melanoma
ret Carcinoma of the thyroid rearrangement
ros Astrocytoma ?
K-sam Carcinoma of stomach amplification -
sis Astrocytoma ?
src Carcinoma of colon ?
trk Carcinoma of thyroid rearrangement-
4..1.5 Role of oncogene amplification in
o •carctnogenests
As noted by Alitalo and Schwab (1986), amplification of certain
oncogenes is a common correlate of the progression of some tumours but
also occurs as a rare sporadic event in various oncogenes in different
types of tumour. Amplified (1" eogenes, whether tumour-type specific or
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sporadic, are also expressed at elevated levels, sometimes ill cells in
which their diploid forms are silent. It is clear, therefore, that increased
expression of an amplified oncogene may contribute to the multi-step
progression of at least some cancers (VeIu., 1990; Gullick, 1991),
including those of the brain (Torp et al., 1991) and, which is of'particular
interest in the context of the present study, secs of the oesophagus
(Hollstein et al.; 1988).
This conclusion is reinforced by Bishop (1991), who notes that gene
amplification is one of four kinds of predispositions to genetic change
that are associated with progression, the others being the loss or gain
of entire chromosomes, widespread loss of lntrcchromosomal domains,
and heightened susceptibility to spontaneous and induced mutations. As
he observes, there may be no requisite order of events in progression,
which appears to be a phenomenon characterised by the accumulation
rather than the sequence of genetic damage.
4.1.6 Aim of Chapter 4
In Chapter 2 it has been shown that the WHeO cell lines, especially
\VHeO-5, constitutively synthesise and secrete relatively high levels of
TGF~a; and Chapter 3 has demonstrated that these cell lines produce
supernumary low-affinity EGF-Rs. The aim of the present Chapter is to
report on the results of DNA hybridisation experiments designed to
determine whether these observations are associated with amplification
of the TGF -(X and EGF -R genes. In the quantitative assessment of the
experimental results, the A431 cell line was used as a control and
standard.
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4.2 Materials and Methods
4.2.1 Plasmid DNA extraction
Escherichia coli transformants containing plasmid DNA bearing TGF-<x
and EGF-R cDNAinserts were grown overnight at 37'>Cin Luria- Bertani
medium (see section Cl of Appendix C) plus 50llg/ml ampicillin
(Boehringer Mannheim). The plasmid DNAwas bulk-extracted according
to the alkali-lysis method of Sambrook ei at. (1989; see section C2 of
Appendix C) and stored at -20·C until required.
4.2.2 Genomic DNA estraetion
The extraction of genomic DNA from the subject cell Iines was based on
the salt method ofMlller et al, (1988) and is described in section C3 of
Appendix C. The concentration of genomic DNA was determined at
260nm using a Beckmann Du-64 spectrophotometer (see section C4 of
Appendix C).
4.2.8 Gene probe preparation
The three DNA probes used in the present study were: the 1.3kb full-
length TGF-a cDNA insert from plasmid pS65C17NJl3 (Derynck et el.,
1984); the linearised 7.0kb EGF-R plasmid (American Type Culture
Collection) encoding a 2.4kb EGF-R internal cDNA sequence (Xu et al.,
1984); and the O.9kb ~-globin intervening sequence II from plasmid
vector pBR322.
To excise and isolate the TGF~(l and f)-globin inserts from their
respective plasmids, the latter were restricted and electrophoretically
78
separated at 100mV on 0.8% TAE agarose gels (see section C5 of
Appendix C). Bacteriophage A. II markers (Boehringer Mannbeim) were
used for calibration purposes. The restriction fragments that
corresprcaied in size to those expected for the two inserts were cut out
of the gels and purified using a Geneclean kit (Bio 101 Inc.; see section
C6 of Appendix C). The TGF-a insert was excised from plasmid
pS65C 17N13 using the EcoRI restriction endonuclease. Excision of the
0.9kb la-globin insert from plasmid vector pBR322 required a double
digestion involving both the EcoRI and BamH1 endonucleases. The EGF-
R probe was prepared by linearising the entire EG:B'-R plasmid using the
HindIII restriction endonuclease. The restriction enzymes were
purchased from Boehringer Mannheim and used according to the
manufacturer's specifications. In order to check both the accuracy of the
endonuclease restriction steps and the efficiencyof the DNApurification
procedure, the restricted TGF-c and J3-gllObinplasmids, together with
their purified inserts and the Iinearised EGF-R plasmid. were
electrophoretically separated at lOOmVon a 0.8%TBE agarose gel (see
sections C7 and CS of Appendix C).
Prior to labelling, the concentration of the purified TGF-a insert and the
linearised EGF-R plasmid was determined by comparison with known
quantities ofa 2.7kbEcoRI-linearised pUC18 plasmid vector (see section
C9 of Appendix C). The concentration of the J3-globin probe was
determined spectrophotometrically.
The three gene probes were finally labelled to a specific activity of 0.67
to 3.07:li:10gdpm/pg DNA with deoxyader-osine 5'[a3?Pl triphosphate
(3000Ci/mmol; Amersham) using a Multiprime DNA labeiling kit
(Amersham; see section C10 of Appendix C). The specific activity was
calculated using the equations set out in section CIO.l of Appendix C.
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4.2.4 Dot-blot hybridisation
The genomic DNA samples were initially denatured at 1000e for a
period of 10minutes. DNA in the range of 0.5 to 10.01lgwas then dotted
under vacuum. onto a nitrocellulose membrane (Hybond-C extra,
Amersham) using a Bio-Dot microfiltration unit (Bio-Rad) according to
the manufacturer's instructions. The DNA was fixed by baking the
nitrocellulose membrane in a vacuum oven at sooe for 2 hours.
PrehybrichsmIDii of the membrane was carried out at 42°C for
approximately 4 hours in prehybridisation solution (see section Cl1 of
Appendix e). DNA hybridisation was performed by incubating the
membrane in hybridisation solution (prehybridisation solution
containing labelled probe) for 16 hours at 42·C. Stringency washes were
carried out at. 6SoCfor 2x30 minutes in a 0.1% SDS solution containing
consecutively 2x, Ix and 0.5x standard saline citrate (SSe; see section
el1.2 of Appendix C). The membrane was exposed at -70·C to Fuji
Medical X-ray film for 24 to 48 hours. Prior to reprobing, the
nitrocellulose was stripped ofprobe by agitating in boiling 0.1%SDS for
1 hour at room temperature. The autoradiographs were scanned using
a Zeineh laser densitometer and the densitometric data processd by an
IBM I-D autostepover/videophoresis programme (Biomedical
Instruments).
4.3 Results and Discussion
4..8.1 Results of DNA hybridisation experiments
Autoradiographs of the dot-blot DNA hybridisation analyses are shown
inFigures 4.2 and 4.3. Panel a of the Figures shows genomic DNA of the
subject cell lines probed with the 1.3kb EcoRI TGF-a cDNA insert and
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with the HindIII-linearised EGF-R plasmid respectively. Panel b of the
Figures shows the same DNAprobed with the 0.9kb ~-globinintervening
sequence, Hybridisation with the J3-globinprobe was used to standardise
for DNA sample loading and to act as an internal control in the
quantitative assessment of gene am-plification.
a b
1 3 4 1 2 3 4
0.5
1.0
5.0 • • • • •
16.0 • • \\ . • • • •
Figure 4.2 Dot-blot DNA hybridisation analysis of the TGF-a. and ~-globin genes. Panel
a - autoradiograph showing hybridisation of genomic DNA to the 1.3kb EcoRl TGF-a
eDNA probe; exposure time = 2 days. Panel b - autoradiograph showing hybridisation of
the same DNA to the O.9kb p-globin intervening sequence II probe; exposure time = 2
days. The quantity of genomic DNA (J.l.g)is indicated on the left; lanes 1 to 4 are A431,
WHeO-l, -3 and -5 respectively.
The relative intensity of panel a compared with panel b in each of the
two Figures is a qualitative reflection of the degree of gene
amplification. No amplification is indicated in Figure 4.2 whereas Figure
4.3 exhibits significant though varying amplification for each cell line.
In order to quantify the degree ofgene amplification, the intensity of the
hybridisation signals emitted from the lOj.lg array of genomic DNA
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samples was measured using a Zeineh laser densitometer; the results
are shown in columns 2 to 4 of Table ·VIII. The figures in these columns
are density-curve integrals (dei's) based on an average of at least two
readings.
a b
1 2 3 4 1 2 3 4
0.5
1.0 • •
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Figure 4.3 Dot-blot DNA hybridisation analysis of the EGF-R and ~-globin genes. Panel
a - autoradiograph showing hybridisation of genomic DNA to the 7.0kb 1inearised EGF-R
plasmid; exposure time = 1 day. Panel b - autoradiograph showing hybridisation of the
same DNA to the O.9kb j3-g1obinIntervening sequence nprobe; exposure time = 1 day. The
quantity of genomic DNA (f.l.g)is indicated on the left; lanes 1 to 4 are A4S1, WHeO-!" -3
and -5 respectively.
The ratio of column 2 (or column 3) to column 4 may be used to calculate
gene amplification. Thus, as regards the A43l cell line, the ratio of the
value in column 3 to that in column 4 (27539.0/17079.5 = 1.612) is
deemed to correspond to the accepted 30-fold amplification ofthe EGF-R
gene in this cell line (Merlino et al., 1984; Gope et al., 1991). Hence,
amplification of the EGF-R gene in the WHCO cell lines may be
calculated as !heir corresponding ratios divided by 1.612 (the A431 ratio)
and multiplied by 30. Amplification of the 'rGF-a gene may be calculated
Jli .....
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in the same way,mutatis mutandis, except that the multiplicative factor
is not 30 but unity because, to the best of my knowledge, there is no
evidence for TGF-a gene amplification in the A431 cell line. The degree
of amplification for the TGF-a and EGF-R genes is shown in rounded
form in columns 5 and 6 of Table VIn respectively.
Table VIII TGF-o and EGF-R gene amplification
Gene
Cell line dei (TGF.-a) dei (EGF-R) dei (p.globin) amplification
TGF- (Y. EGF-R
A481 15300.5 27539.0 17079.5 Ix 30x
WHCO-! 8538.5 4951.0 11644.5 Ix 8x-
WHCO·3 22653.0 22223.7 16423.0 2x 25x
WHeO-1S 17960.5 6487.5 13027.5 2x 9x
The amplification figures were calculated as described in section 4.3.1. Amplification is
deemed to have been detected only ifit exceeds 3-fold.
4..3.2 Amplification of the TGF-a gene
As discussed in Chapter 2, the WHeO-l, -3 and -5 cell lines secrete
appreciable quantitiies of TGF-a under unstimulated serum-free
conditions. The quantity secreted byWHCO-5is approximately ,41times
that secreted by the A4,31cell line and appears to be relatively high for
a neoplast.ic cell line" Using the A431 cell 1i.TJ.8 as a negative control and
standard, I have shown above that this oversecretion is not the result of
TGF-a gene amplification, The WHCO-l and -3 cell lines - which, as
may be inferred from Table III, secrete respectively 1.5 and 2.5 times as
much rrGF~c.xas the A431 cell line - also lack amplified TGF~a.sequences.
These results are consistent with those reported elsewhere. Yoshida Pot
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al. (1990) did not detect TGF-a gene amplification or rearrangement i.'l
a number of human oesophageal sec cell lines that expressed high
levels ofTGF-a mRNA. Of course, TGF-a mRNA overexpression is not
a sufficient condition for over secretion of TGF-a protein. Because
cleavage is a rate-limiting step in the generation of soluble TGF -c, it
would appear that an enhanced ability of cells to cleave TGF-a from.
their transmembrane precursors is also a necessary condition for TGF-a.:
oversecretion. The mechanisms associated with enhanced pro-TGF-a.:
cleavage have been discussed at length in Chapter 2.
4.3.8 Amplification of the EGF",Rgene
In oesophageal SCGs, it has been demonstrated in several studies that
overexpression of the EGF-R is frequently associated with receptor gene
amplification. In primary oesophageal tumours, Lu et al, (1988) have
reported at least 4-fold amplification, and Hollstein et al. (1988) at least
10-fold amplification. Regarding derived cell lines, unspecified levels of
amplification are reported in Yamamoto et al. (1986) and Yoshida et al.
(1990).
In the light of the above, the existence of amplified EGF-R gene
sequences in the WHCO cell lines (see Table VIII) is unsurprising;
moreover, the degree of amplification is not inconsistent with that
reported elsewhere. As may be seen from Table IX, there is a strong
positive correlation between EGF-R gene amplification and protein
overexpression in the VVHCO cell lines, which was noted in Jones et al.
(1992).
A similar relationship has been demonstrated in clonal sublines of A431
cells (Lin et al., 1984), and in certain other sec cell lines (Reiss et al.,
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1991). Although levels of EGF-R mRNA were not evaluated in the
present study, it is no matter for surprise that there exists a positive
correlation between EGF-R gene amplification and an intermediate stage
in the hyperproduction of its protein, namel ~.rverexpression of EGF-R
mRNA, in oesophageal sees (Lu et al'J 1988; Yoshida et al., 1990;
Hollstein et al., 1988).
Table IX Comparison of EGF-R gene amplification ani, protein
overexpression
Cell line EGF-Rgene Level of EGF-R protein
8mplUication expression'
WHCO-l 8x 8x ,,-
WHCO-3 25x 23x
WHCO-5 9x 12x
1 level measured relative to that of normal oesophageal keratinocytes, from Chapter 3,
Table VI.
Extra gene copies can arise from a true gene amplification - that is,
duplication. of a chromosomal region localised around the gene - or from
polyploidy of chromosome 7, which bears the EGF-R gene locus (Hurtt
et al., 1992). One would speculate that the higher the observed level of
EGF-R gene amplification, the less Lkely it is that chromosome 7
polyploidy has a significant role. Thus" !raryotypic studies of the WHeO-
3 cell line, which has a high level of receptor gene amplification, have
shown that such amplification is not the result of chromosome 7
polyploidy, but may arise from tandem gene duplications (Heiss, 1992).
It is unknown whether polyploidy ofchromosome 7 is implicated in EGF-
R gene amplification in the WHeO-1 and -5 cell lines as no karyotypic
studies of these lines have been undertaken to date.
In concluding this discussion, it is appropriate to note that the
85
expression of supemumary EGF-Rs may arise from mechanisms other
than gene amplification, including mRNA overexpression (Hollstein et
al., 1988; Lemoine et al., 1992), defective receptor downregulation
(Masui et al., 1991; Reiss et al., 1991) and ligand ..induced receptor
production (Bjorge et al., 1989; Kearsley er al., 1991). Indeed, one or
other of these mechanisms may play a contributory role even in the
presence of gene amplification.
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Chapter 5
Concluding Discussion
5.1 Aim of Chapter 5
Like Janus, this Chapter looks forward as well as backward, because an
ending is also a beginning. Its chief concern is retn,
the development of a synoptic view of the main subscantive points of
Chapters 2, 3 and 4. This is presented in sections 5.2 to 5.5. '111-3
prospective final section puts forward some thoughts on the structuring
of future research on the WHCO cell lines.
5.2 Transforming growth factor alpha {Chapter 2)
5.2.1 Constitutive production and secretion of
TGF-a
/ '''\
The production and secretion ofTGF-a hythe A431 and WHCO cell lines
and their biological response to exogenous mature TGF-a were examined
ill Chapter 2.
(
My results show that, under unstimulated serum-free conditions (section
2.3.1), the A431 and WHCO cell lines constitutively secrete appreciable
quantities of'rGF-a over a period of 20 hours. The level of TGF-a
secretion by \VHCO-5 cells appears to be relatively high. fm' a neoplastic
cell line and its short doubling time may be attributable to . rignalling
defect involving constitutive overexpression of TGF-a and the EGF;-R~
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possibly coupled with the relative dysfunction of'some inhibitory factor
such as TGF-~. Two distinct species ofTGF-a were found in the lysates
ofunstimulated cells. 'Ihe lower molecular weight forms were consistent
with reports in the literature for various species of pl'o-TGF-a. The
higher molecular weight forms were likewise consistent with known
findings for meso-TGF-n and are of particular interest because, being
cell-associated rather than secreted, they are suggestive of an autocrine
mode of action.
My results also show that, compared with unstimulated or basal levels
of TGlt'-a sec.etion, the presence of this growth factor in secreted form
is augmented by exogenous PMA, FBS and EG}i' to an extent that is
statistically significant at a 5% level of confidence or better. The
consistency between these results and those reported in the literature
is described in section 2.3.2 and need not be repeated here. Regarding
PMA, however, it is of interest to note that the rapid nature of the
cleavage response suggests that thi PKC-dependent mechanism does
not rely upon the relatively time-consuming synthesis ofpro-TGF-a. but
rather upon activation of some essential cleavage enzyme, increased
exposure of pro-TGF-a to this enzyme or its conversion to a better
substrate for the enzyme. It is also noteworthy that exogenous EGF
appreciably and autoinductively increases the accumulation ofTGF-CY.in
the media conditioned by the A431 and WHCO cell lines, particularly
WHeO-5. These results necessarily involve the relatively lengthy process
of TGF-a. gene expression but also imply an enhanced cleavage
efficiency,which may well be linked to PKC activation.
It is surpnsmg to observe from the immunoprobe analysis of
m:Mt;mulated and stimulated cells that the intensities of the bands
appear to be independent of stimulation. Unlike FBS, PMA and EGF
apparently inhibit differential glycosylation. In the case ofmeso-'l'GF-a
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species, they may favour cleavage at the lys96 _ly::;97cleavage site.
5.2.2 Cell proliferation and' colony formation
ll~ssays
The A4:31 and WHGO cel1lines secrete TGF-a constitutively and to
overexpress EGF -Rs. Cell proliferation and colony formation assays were
carried out to determine the effects of exogenous TGF -o em. the
proliferative and migratory behaviour of the cell lines in vitro.
The proliferation profiles of the subject cell lines in. response to
exogenous TGF-a vary appreciably (Figure 2.9), As noted in section
2.3.3, the profiles for A431, WHCO-l and WHCO-5 are consistent with
results reported in the literature. In the latter caee, it is suggested that
the decline in proliferation from O.lnghnl onwards may be attributable
to increasing down-regulation and desensitisation of the EGF-R.
From the colony formation assays (Figure 2.10 and Table V) it would
appear that exogenous TGF -c inhibita the formation of colonies in the
A431 cell line (as reported elsewhere) and WHCO-5 call line but
promotes it in the WHCO-l cell line. Regarding WHCO-3, the addition
of TGF -a yields fewer but larger and more diffuse colonies. This result.
which is suggestive of cell migration, is in accordance with some of my
earlier research (Jones 1989).
5.3 The epidermal growth factor receptor
(Chapter 3)
In Thornley and Jones (1992), it was proposed that the unusually short
doubling time of the WHCO-5 cell line may be partly the result of a
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signalling defect involving overexpression of TGF-a and low-affinity
EGF-Rs. The principal aim of the experiments described in Chapter 3
was to determine the hitherto unknown number and affinity ofEGF-Rs
in this cell line.
Table Vl shows the number of EGEI-Rn per cell and dissociation
constants for the A431 and WHCO cell lines, The values obtained for the
A431 and 'w\'HCO-3cell lines are in good agreement with those reported
in the literature; those for the WHCO-5 «ell line lend support to the
abovementioned proposal in Thomley and Jones (1992).
Hyperproduction ofEGF -Es has been described as the hallmark ofSCCs.
Overexpression of low-affinity EGF'-Rs han recently been noted in a
number of oesophageal SCC cell lines. The rp,sults of the present study
are congruent with this literature and serve ttl confirm and extend those
reported in Veale and Thornley (J.989).
5.4 Gene amplification (Chapter' 4)
The WHCO cell lines, especially WHCO-5, constitutively synthesise and
secrete relatively high levels ofTGF-a; they also prod' _',ernumary
low-affinity EGF-Rs. The aim of Chapter 4 was to determine whether
these phenomena are associated with amplification of the TGF-~ and
EG!!·nR. genes.
Estimates of gene amplification in the subject cell lines are given in
Table: VIII. As may be seen, there is no evidence of TGF·a gene
amplification, a result that if! in accordance with the literature. On the
other hand, amplification of the EGF-R gene, which is known to occur
in A431 calls, is also found to be a pronounced characteristic of the
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WHCO cells. This result is not surprising in the light of other research
into primary oesophageal tumours and derived cell lines. Moreover,
there is in the WHCO cell lines a strong positive correlation between
EGF-R gene amplification and protein overexpression (Table IX).
5.5 Conclusions
There is extensive evidence in the Iiterature that TGF·a interacts with
the EGF-R by means of an autoerine pathway that ~s regulated in
normal but deregulated in neoplastic cells, mrt .;'" the latter confers a
growth advantage that is important to tumour progression. In general,
overproduction of an autocrine growth factor ~s not sufficient for
malignant transformation. Thus. although Fischer l:a~fibroblasts are
transformed in vitro following transfection with a human TGF-c cDNA
expression vector (Rosenthal et al., 1986)?overexpression of TGF-a in
skin keratinocytes results only in the formation of hyperplastic
epidermis but not of tumours (Finzi et al., 1988). Complete
transformation appears to require at least a second defect in the
autocrine signalling pathway. Therefore one would expect neoplastic
cells to display overproduction of an autocrine mitogen coupled with a
defect in one or more of the mechanisms which regulate the activity of
its receptor.
The summary of findings set out in sections 5.2 to 5.4, which accords
with the observations in the preceding paragraph, would appear to
indicate that TGF-a and its receptor interact via an amplified autocrine
pathway in certain oesophageal SCCs of the WECO series. First, it has
been demonstrated that the subject WHCO cell lines not only
constitutively produce. and secrete significant quantities of TGlr-a but
also concomitantly overexpress low-affinity EGF-Rs. These results are
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in accordance with the suggestion in Cutry et al. (1988) that TGF-(l may
be primarily dependent on this class ofEGF-R for eliciting its mitogenic
effect. Secondly, the seemingly novel identification of cell-associated
meso-T'Gli'-c is indicative of an autocrine (or intracrine) pathway.
Finally, the ability of exogenous EGF to significantly enhance the
accumulation of secreted TGF-a points to the existence of a functional
autoinductive pathway. These findings support the conclusions
concerning an autocrine role for TGF-e reached in various other studies
of oesophageal secs, such as Yoshida et al. (1990).
In general, TGF-a acts to promote cellular proliferation and migration
and, in vivo, tumour expansion, metastasis and neovascularisation. The
aforementioned proliferation and colonyformation assays were designed
to examine the effects of exogenous TGF-a on proliferation and
migration in the subject cell Jines. The resulting proliferation profiles
were varied, as is often found in the literature, but in all cases
exogenous rrGF~(lstimulated proliferation above basal levels. Exogenous
TGF-o had no uniform effect on colony formation in the subject cell
lines; the fewer but larger and more diffuse colonies observed in the
WHCO-3 cell line are suggestive of cell migration. These results are
consistent with TGF-a's well-known role as a mitogenic factor.
It should be noted that most oesophageal carcinoma tissues obtained
from surgical specimens express higher levels ofTGF -\X and EGF-R than
does normal oesophageal tissue (Yoshidaet al., 1990). This encourages
one to believe that the results and conclusions reported in this study are
not mere in vitro artifacts but are likely to have relevance in the
progression of primary tumours such as those from which the WHCO
cell lines were derived.
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5..6 Thoughts on future research
It is desirable that the experiments that form the basis of this study be
repeated in the context of an improved experimental design. It is clearly
important to establish the reasons for the constitutive secretion oftfGF-
a by the subject cell lines. Inter alia, this may be attributable to
rearrangement of the TGF-a gene sequence, which Southern blot
analysis would help to clarify; or to the action of some oncoprotein (such
as p21), the presence of which could be detected by Western blot
analysis. Northern blot analysis could be used to test the validity of my
speculation that the unusually high constitutive secretion ofTGF-a by
the WHCO-5 cell line may be ascribable to overexprcssion and enhanced
stability of messenger transcript. As regards the EGF-R, it would be of
interest to refine the analysis ofreceptor affinity by the use of antibodies
directed specifically at the supernumary low-affinity class known to be
present: only thus would it be possible to determine whether or not a
relatively small number of high-affinity receptors is also present. As
regards EGF-R gene amplification, the use of Southern blot analysis
would shed light on whether the receptor gene sequence is rearranged,
which would be indicative of the presence ofaberrantmRNA transcripts
and protein products. In particular, my conclusion that there is an
autoerine relationship between TGF-a and the EGF-R in the subject cell
lines needs to be exposed to the rigorous proof that would be afforded by
the use of appropriate antisense constructs or specific antibodies in
blocking experiments such as those described in Stromberg et al. (1992).
Like the present study, the above outline of directions for further
research focuses narrowly on aspects of the TGF-alEGF-R autocrine
pathway. But tumourigenesis is a complex, multi-step process, and
therefore one must keep in mind that other mechanisms that impinge
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on this pathway may reinforce it when deregulated. Work is being
undertaken on the secretion and action of TGF~f3in the WHCO cell
lines, and this is of importance in the present context because, as
mentioned in section 1.3.1 ofChapter 1, TGF-(3 modulates the effects of
TGF-(X.Alsorelevant is the overexpressionofc-Mycb, the WHCO-3cell
line (Heiss 1992) in view of the fact, discussed in section 1.3.3 of
Chapter 1, that transcription factors have an important role in
controlling the functional activity of growth factors in mutually
interactive autocrine loops. In evaluating the results of the proposed
research programme, it would be necessary to take account of the
findings that may emerge from such parallel lines of enquiry.
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Appendix A
Al Phosphate buffered saline (pH 7.6)
137mM NaCI, 2.7mM KCI, 1.5mM KH:.tP04JB.lmM Na2HP04.12H20.
Make up with Milli-Q water and filter sterilise. For routine laboratory
use make up with distilled water.
A2 Radioimmunoassays
A2.1 Radioimmunoassay m/'J..J--l(Jlogy
I
Reconstituted conditioned metntlIIl samples (100~1) were placed in
12x75-mm plastic tubes and incubated at 4°C with 50~ per tube of
sheep anti-human TGF-a. antiserum for 24 hours. One hundred
mio»-litres of 125I_TGF-(l.were added to each tube and the mixtures left
for a further 24 hours at 4°C. On day three, 100~ of precipitating
donkey anti-sheep antiserum were added to each tube and the mixtures
incubated for 15 minutes at room temperature. After the addition of
1.5m1of chilled TBS (pH 8.5), the mixtures were vortexed, centrifuged
at 2500rpm for 15 minutes in an MSE bench-top centrifuge and their
supernatants decanted. The radioactivity present in the immunoglobulin
pellets was determined by counting for 2 minutes in a Packard Cobra
auto-gamma counter. The assay's sensitivity and half-maximal
displacement were quoted as O.02ngTGF-wtube and 1.7nglml TGF-a.
respectively.
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A2.2
Table Al Radioimunoassay 1 - data and statistical analysis
Point dpm sdpm a (%) f3 No C Test
T V
NSB 270.47 0.00
Bo 9336.22 9065.75 100.00
81 8914.97 8644.50 95.35
82 7390.10 7119.63 78.53
83 6049.72 5779.25 63.75
S4 2062.47 1792.00 19.77
85 1699.72 1429.25 15.77
SFM 9251.60 8981.13 99.07 *
SFCM(A) 8750.60 8480.13 93.54 0.037 2.05xl07 3.6 t 4.01
8FCM(3) 8604.47 8334.00 91.93 0.048 9.86xl06 9.7 t 4.42
SM 9396.97 9126.50 100.67 *
8FCM(A) 8750.60 8480.13 93.54 0.037 2.05x107 3.6.
SsCM(A) 8024.97 7754.50 85.54 0.088 2.71xl07 6.5 U 1.4%
8FCM(S) 8604.47 8334.00 91.93 0.048 9.86x106 9.7
SsCM(3) 8301.10 8030.63 88.58 0.068 1.02xl07 13.4 t 2.35
N8B = non-specific 12bI_TGF_abinding; B, = maximum 125I-TGF-a binding; 8(1-5) =
standard TGF-a concentrations, where 81 = O.025ng/ml, 82 =' O.liOng/ml, 83 =
0.250ng/ml, 84 = 1.380ng/ml, 85 = 2.500nglml; SFM = serum-free medium (DME~rtF12,
3:1); 8FCM(A} = unstimulated serum-free conditioned medium, A431; SFCM(S) =
unstimulated serum-free conditioned medium, WHCO-3; SM = unconditioned serum-
containing medium (DMEM/F12 + 10%FBS); SsCM(A) = serum-stimulated conditioned
medium, A431; SsCM(3) = serum-stimulated conditioned medium, WHCO-3; dpm =
average number of disintegrations per minute; sdpm = average number of specific
disintegrations per minute (i.e. dpm - 270.47); a (%) = [sdpml9065.75] x 100; f3 =
concentration (ng/ml) ofTGF-a in lOx concentrated medium samples [:-::(2-loga)/0.777J; *
= concentration below assay sensitivity; No ::: number of cells conditioning 20ml of
unconcentrated medium; C :.::quantity ofTGF-a secreted ill 20 hours in units of pg/106
cells; T = type of statistical test, t representing Student's t test and U the Mann-Whitney
test; V = value of test. The U values are a precise measure of the Ievel of confidence on a
one-tailed basis. At a 5% leve1of confidence, the critical value of Student's t for a one-tailed
test with six degrees of freedom is ± 1.94. Note~ The correlation coefficient and standard
error of the above linear regression equation rp=(2-loga)/0.777] are -0.999 and 2.566x10-3
respectively.
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Table A2 Radioimmunoassay 2 - data and statistical analysis
Point dnm sdpm ex (%) P Ne C Test
T V
N8B 233.60 0.00
Bo 5963.22 5729.62 100.00
81 5533.72 5200.12 92.50-
82 4600.72 4367.12 76.22
!----
S3 3813.97 3580.37 62.49
84 999.35 765.75 13.36
85 762,22 528.62 9.23
8FM 5775.47 5541.87 96.72 *
SFCM(A) 5486.47 5252.87 91.68 0.032 1.75x107 3.6 t 3.46
8FCM(1) 5289.72 5056.12 88.25 0.053 1.96x107 5.4 U 1.4%
8FCM(3) 5558.72 5325.12 92.91 0.024 5.53x1OS 8.6 U 1.4%
8FCM(3) 5075.72 484-2.12 84.51 0.078 1.86x10" 8.4 t 7.41
8FCM(5) 6129.10 4895.50 85.44 0.07? 9.80xl05 146 t 8.15
18FCM(A) 5486.47 5252.87 91.68 0.032 1.75x107 3.6
PsCM(A) 5366.85 513:3.25 89.59 0.045 1.69xl07 5.3 t 2.26
8FCM(3) 5558.72 5325.12 92.94 0.024 5.53x106 8.6
PsCM(3) 5324.60 5091.00 88.85 0.049 5.53xl06 17.7 t 6.50
8FCM(A) 5486.47 5252.87 91.68 0.032 1.75x107 3.6
EsCM(A) 4693.60 4460.00 77.84 0.126 2.02x107 12.5 U 1.4%
SFCM(1) 5289.72 5056.12 88.25 0.053 1.96x i07 5.4
EsCM(l) 5165.72 4932.12 86.08 0.068 2. llx107 6.4 t 3.52
8FCM(3) 5075.72 4842.12 84.51 0.078 1.86xl07 8.4
EsCM(3) 4792.22 4558.62 79.56 0.113 1.91x107 11.8 t 4.06
8FCM(5) 5129.10 4895.50 85.44 0.072 9.8xl<Y' 146.0
I EsC~~) 1591.22 1357.62 23.69 1.014 1.4x1011 1449 t 67.3
N8B = non-specific 125I-TGF··a binding; B, = maximum 125I-TGF-a binding; 8(1·5) =
standard TGF-a concentrations, where 81 = O.025ng/ml, 82 = 0.140ng/ml, sa =
0.250ng/ml, S4 = 1.380nglml, 85 ::;2.500ng/ml; SFM = serum-free medium (DMEMlF12,
3:1); SFCM(A) = unstimulated serum-free conditioned medium, A431; 8FCM(1) ""
unstimulated serum-free conditioned medium, WHCO-l; SFCM(3) = unstimulated serum-
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free conditioned medium, WHCO-3; SFCM(5) = unstimulated serum-free conditioned
medium, "'NHCO-5;PsCM(A) = PMA-stimulated conditioned medium, A431; PsCM(3) =
PMA-stimulated conditioned medium, WHCO-3; EsCM(A)= EGF-stimulated serum-free
conditioned medium, A431; EsCltf(l) = EGF-stimulated serum-free conditioned medium,
WHCO-l; EsCM(3) =EGF -stimulated serum-free conditioned medium, WHCO-3; EsCM(5)
= EGF-stimulated serum-free conditioned medium, WHCO-5; dpm = average number of
disintegrations per minute; sdpm = average number of specific disintegrations per minute
(i.e. dpm - 233.60); a (%) = [sdpml5729.62] x 100; 13 = concentration (nglml) of TGF-a in
lOx concentrated medium samples [= (1.986-1oga)/0.7551;* = concentration below assay
sensitivity; N.. = number of cells conditioning 20ml of unconcentratec1 medium; C =
quantity of TGF-a secreted in 20 hours in units of pg/10&cells; T = Statistical test, t
representing Student's t test and U the Mann-Whitney test; V = value of test. The U
values are a precise measure of the level of confidence on a one-tailed basis. At a 5% level
of confidence, the critical value of Jtucent's t for a one-tailed test with six degrees of
freedom is ± 1.94. Nete: The coI"''''b.tion coofficient and standard error of the above linear
regression equation C(3=(1.986-10gtt}iO.755Tare-=LOOand 1.362:;(1.0-3respectively
AS Detachment solution
1,.'?5mlPMSF/methanol stock, 2.50ml trasylol stock. Make up to 250ml
with PBS.
(PMSF/mcthanol stock: 34.8mg PMSF in 10ml methanol; trasylol stock:
14mg trasylol in 10ml PBS).
A4 Electrophoresis sample buffer (pH 6.8)
Iml glycerol, 0.5m1 ~-mercaptoethanol, 0.3g SDS, O.15g Tris. Make up
to lOrn! with distilled water.
A5 SDS polyacrylamide gel electrophoresis
.0.45.1 10-20% gradient gels
Stacking gel (5% acrylamide): 0.48g acrylamide, 2.5m1 stacking buffer
solution (O.5MTris, pH 6.8), D.4ml SDS solution (50mglml), 0.55m! bis-
acrylamide solution (25mg/m1). Make up to 10ml with distilled water.
Add 32111TEMED and 1301111.25% ammonium persulphate solution
(APS).
Separating gel (10% acrylamide): O.6g acrylamide, 1.5m! separating
buffer solution (1.5M Tris, pH 8.8), O.24m! SDS solution, O.24m! bis-
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acrylamide solution. Make up to 6mI with distilled water. A.:ld I81l1
TE:MEDand 80~ APS.
Separating gel (20% acrylamie, .' 1.2g acrylamide, 1.5mI separating
buffer solution, 0.24m! SDS solution, O.24ml bis-acrylamide solution,
1.5ml 20% glycerol. Make up to '3.all with distilled water. Add 18J.Ll
'fEMED and 80lli APR
...1.&.2 Running buffer (p.H B.tl-8.4)
2.4~g Tris, O.BOg SDS, II.5Sg glycine. Make up to 800m! with -distilled
water.
A5.3 Transfer buffer (pH 8.3)
42.3g glycine, 9.0g Tris, GOOmlmethanol, Mak~ up to :3 litres with
distilled water,
A6 Blocking buffer (pH S.O}
0.606g Tris, 4.383g NaCI, O.25mlTween-20, 2.5g non-fat milk powder.
Make up to 500ml with distilled water.
A7 TBS Tween·20 (pH 8.0>
O.S06gTris, 4.383g NaCI, 0.25m! Tween-20. Make up to 500m! with
distilled water.
AS Antibodies
AB.l Primary
AB.1.1 Polyclonal anti-human TGF-a (Biomedical Technologies Inc.)
This highly specific sheep polyclonal antiserum was raised against
human TGF-a and does not cross-react under radioimmunoassay
conditions with either recombinant rat TG:F'-a or human EGF. The
antibody was ,:, .uted 1:2.5 in TBST for use as a primary imruunoprobe.
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AS.1.2 lr tonal anti-human TGF-a. (Oncogene Science)
This UOt,($B monoclonal antibogy (IgGl) was produced by immunising
mice with recombinant human TGE'-<x.The antibody reacts with native
and denatured. forms of rat and human mature TGF-<x but shews no
cross-reactivity with human or mouse EGF. The antibody was diluted in
TBS1' and used as a primary iromunoprobe at a concentration of
10Jlg/mI.
AB ..2 Secondary
A8.2.1 Polyclonal donkey anti-sheep (The Binding Site)
The donkey anti-sheep peroxidase-conjugated (heavy and light chain
specific) IgG stock solution was diluted in TBST and used at a
concentration of 1:200.
A8.2.2 Polyclonal goat anti-mouse (Sigma)
The goat anti-mouse peroxidase-conjugated (Fab specific) IgG stock
solution - ~s diluted in TBST and used at a concentration of 1:100.
A9 4-chlora. I-naptbol substrate solution
2ml4-chloro-1-napthol stock, 60Jll hydrogen peroxide, 48 ml P:B~.
(4-chloro-1-napthol stock: 0.15g 4-chloro-1-napthol. Make up to 50 ml
with methanol.)
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AppendixB
Table Bl A431 125I_EGF competitive binding data
-_.1'-
p... a ~ Vt dpm sdpm
1 .77 0 91-1.5 22665 16827
2 .77 90 914.5 5838 0
3 .77 0.01 914.5 25845 20007._
4 .77 0.1 914.5 24423 18585
5 .77 0.5 914.5 22524 16686
6 .77 1.0 914.5 22670 16832
7 .77 6.0 914.5 18192 12354
8 .77 10.0 914.5 16539 10701
9 .77 15.0 914.5 13645 7867
Pn = point number; ex= total amount (ng) of 1215I_EGFper point; ~ = total amount (ng) of
receptor grade EGF per point; V, :::total volume of competitive binding solution per point;
dpm = average number of disintegrations per minute; sdpm :::average number of specific
disintegrations per minute (i.e. dpm ~5838); volume of competitive binding solution added
per wen::: 290 ul; number of cells per well= 1.31xl05; % non-specific binding (i.e. [dpm for
point number 2/dpm for point number 1] x 100) = 25.76%.
(
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Table B2 WHCOM3 125I_EGF competitive binding data
---
Pl1 a f3 v, dpm sdpm
1 .81 0 915 24698 21888
2 .81 9() 915 2810 0
3 .81 0.01 915 25098 22288
4 .81 0.10 915 25228 22418-
5 .81 0.5 915 ~3880 21070
6 .81 1.0 915 23271 20461
7 .81 2.0 915 21368 18558
8 •81 6.0 c 915. 13872 11082
9 .81 10.0 915 11738 8928
1?O 1915
,-,-
10 ,81 10490 7680 _.J..
Pa • r oint number; ~ total amount (ng') of 126I-EGF per point; Il= total amount (ng) of
receptor grade EGF per point; Vt = total volume of competitive binding solution per point;
dpm = average number of disintegrations 'Per minute; sdpm = average number of specific
disintegrations per minute (i.e. dpm -2810);volume of competitive binding solution added
per well = 296 111;number of cells per well= 1.35xl05; % non-specific binding (i.e, [dpm for
point number 21dpm for point number 1] x 100)= 11.38%.
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Table B3 WHCO-5 125I_EGF competitive binding data
Pn (l. ~ v, dpm sdpm
.J_ ,81 0 915 13286 117f.l7
2 .81 90 915 1499 0
3 .81 .1 915 13227 il'J28
4 .81 0.5 915 12067 10568
5 .81 1.0 915 7041 5542
6 .81 6.0 915 6758 5259
7 .81 10.0 915 53';0 3851
8 .81 1;).0 915 4428 2929
9 .81 20.0 915 3704 2205
P, = point number; a. = total amount (ng) of 126I_EGFper point; f3 = total amount (ng) of
receptor grade EGF per point; Vt :: total volume of competitive binding solution per point;
dpm = average number of disintegrations per minute; sdp""1 ::::average number of specific
disintegrations per minute (i.e. dpm - 1499; volume of competitive binding solution added
per well = 300 Ill; number of'cells per well: 1.13x105;% non-specific binding (i,e,[dpm for
point number 21dpm for point number 1]x 100)= 11.28%.
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Appendix C
ci Luria-Bertani medium (pH 7.6)
1% tryptone; 0.5% yeast extract; 1% NaCl. Make up in autoclaved
distilled water.
C2 Large scale preparation of plasmid DNA
Bacterial transformants were harvested by centrifugation at 6000rpm
(DuPont RC-5 Sorvall centrifuge) for 10 minutes. The bacterial cell
...rellets were resuspended in 5ml of Solution I (see section C2.1) and
incubated at room temperature for 10 minutes. The cells were lysed by
the addition of lOml of Solution II (cee section C2.2), and their linear
DNAs digested at room temperature for 15 minutes, Next, 7.5ml of
Solution III (see section C2.3) were added and the bacterial proteins
precipitated on ice for a period of 10 minutes. The cellular debris was
pelleted by centrifugation at 16000 rpm and ·:t°efor 15 minutes, and the
undigested DNAs precipitated for 15 minutes following the addition of
0.6 volumes of isopropanol. The precipitated DNAs were isolated by
centrifuging for 10 minutes at 15000rpm and 25°C, rinsed with 5ml of
ethanol, vacuum-dried (Sarvant Speedvac concentrator) for 15 minutes,
and resuspended at 45°C over a period of 2 hours in 4ml of Tris-EDTA
(TE; see section C2.4). Following the addition of 4g of caesium chloride
(CsCl) and OAm] of a 10mg/ml ethidium bromide (EtBr) solution, the
refractive index of the mixture was adjusted to 1.389 using an Atago
refractometer. The mixture was aliquoted into Beckmann Quickseal
tubes and ultracentrifuged (Beckmann L7-65 ultracentrifuge) at
45000rpm and 10°C for 16 hours using' a V'li65.2 rotor. The supercoiled
plasmid DNA was carefully aspirated through an 18-gauge needle and
aliquoted into Eppendorf tubes. Finally, the intercalated Ettlr was
phase-extracted 3 to 4 times with an equal volume of 'Iris-saturated
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butanol (O.lM 'Iris/butanol, 1:1), and the CsCI removed from solution by
dialysing at room temperature for 4 hours in 2 changes cf autoclaved
distilled water.
C2.1 Solution I (pH 8.0)
50mM glucose; 25mM Tris; 10mM EDTA. Make up in autoc1aved
distilled water. Add 5mg of lysozyme (Sigma) per m.l of solution.
C2.2 Solution II
0.2M NaOH; 10%SDS. Make up in autoc1aved distilled water.
C2.3 Solution III (pH 5.5)
5M potassium acetate; Llrnl glacial acetic acid. Make up to 100 ml in
autoclaved distilled water.
C2.4 TE (pH 8.0)
10mlVITris; 10mM EDTA-Na2.2H20. Make up in autoclaved distilled
water.
C3 Salt extraction of ge......nmie DNA
The cell monolayers were briefly rinsed in PBS and harvested by
scraping in 1ml of STE (see section C3.1) per tissue ..ulture dish. The
cells were subsequently lysed in 1% SDS. Proteinase K (Boehringer
Mannheim) was added to a final concentration of 2mg/ml and the
mixture incubated at 55"C for 16 hOl.U'S. The cellular proteins were
precipitated by the addition of 500J.Ll(per ml of S'I'E) of a 6M NaCI
solution, and pelleted at 3000rpm (DuPont RC-5 Sorvall centrifuge) for
20 minutes. The genomic DNA was precipitated with 2.5 volumes of
absolute ethanol, spooled out of solution and rinsed with 70% ethanol.
The DNA was vacuum-dried (Savant S:peedvac concentrator) for 20
minutes and finally resuspended overnight at 45"C in 0.5ml of
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autoelaved distilled water.
C3.1 STE (pH 8.0)
O.IM NaCl; O.05M Tris; ImM ED'l"A-Na2.2H20. Make up in autoclaved
distilled water.
C4
Table Cl Spectrophotometric determination of genomic DNA
concentration.
Cell ~me OD2GOnm ttg/ml1 J,tg/J.L].2
A431 0.202 10.1 1.01
WHCO-l 0.132 6.6 0.66.
WHCO-3 0.346 17.3 1.73
',-
WHCO·5 0.174 8.7 0.87
lOne OD26Omn unit lit 50ILWmldouble stranded DNA.
2 Concentration of neat genomic DNA (sample analysed was diluted 100 times).
C5 0.8%T.AEagarose gel
1025ml of 40x TAE running buffer; 2.5Jll of a LOmg/ml EtBr solution;
OAg agarose. Make up to 50ml with autoclaved distilled water.
C5.1 40x TAE running buffer (PH 7.2)
106MTris; O.BM Na acetate.3H20; 40mM EDTA-Na2.2H20. Make up in
autoclaved distilled water.
C6 Purification of gene inserts
The TGF -c and f3-globin inserta were excised from the TAE agarose g(;Js;
weighed and dissolved in approximately 3 volumes ofNaI for 10 minutes
at 55°C. The inserts were allowed to bind to a glassmilk suspension (l~ll
suspension/ug DNA) for 15 minutes on ice. The glassmilkIDNA
complexes were pelleted by microfuging (Eppendorf 5413 microfuge) for
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5 minutes and washed 3 times with 50 volumes of ice-cold New Wash
solution. The washed pellets were resuspended in an equal volume ~;,!
autoelaved distilled water and the DNAs solubi1ised at 55°C for 2 /,,,,0
minutes. The glassmilk suspensions were pelleted by microfuging fh:r j\}
seconds and the supernatants containing the elu: ed DNAs carefully
removed and stored at -20"C.
C7 0.8% 'r'BE agarose gel
2.5inl of 20x TBE running bum . 7111 of a 10mglmlF.JJlyolutioh; OAg
agarose. Make up to 50ml with autoclaved distilled water.
C7.1 20x TBE running buffer (pH B.2)
lM Tris; 1M boric acid; 20mM EDTA-N~.2H20. Make up in autoclaved
distilled water.
C7.2 DNA loading buffer (5x)
50% glycerol; 20% O.5MEDTA-Na2.2H20; 5ml TBE running buffer; 10%
bromophenol blue •.Make up to 100ml with autoclaved distilled water.
Add 2Jj~ to DNA samples prior to loading.
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C8
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2.0
23.1
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4.4
8.56
Figure Cl 0.8%TEE agarose gel showing restricted plasmids and purified inserts. Lane
1, 1.3kb full-length TGF-a eDNA insert and the 3.5kb plasmid vector; lane 2, purified
TGF-a insert; lane 3,linearised 7.0kb EGF-R plasmid; lane 4, O.9kb 13-g1obinintervening
sequence IT and the 4kb pBR322 plasmid vector; lane 5, purified 13-g1ohininsert. The
molecular sizes (kb) of the A. II DNA markers are indicated on the left.
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C9
1 2 3 4 5
2.3
2.0
23.1
9.4
6.6
4.4
Figure C2 Probe concentration assessement by dilution analysis. 0.6% TBE agarcse gel
showing: lane 1, unknown quantity (if. the purified 1.3kb TGP-a eDNA insert; IMe 2,
unknown quantity of the 7.0kb linearised EGF-R plasmid; lanes 3 to 5 - 22.5ng, 45ngand
gOng of a linearised 2.7kb pUC18 plasmid vector. The molecular sizes of the A. II DNA
markers are indicated on the left.
CIO Multiprime labelling of DNAprobes
25 to 100ng of DNA probe was denatured at 100"C for 5 minutes. The
denatured probe was added to a reaction mixture comprising: 4Jll each
of dCTP, dTTP and dGTP; 5J.L].each oflabelling buffer, primer and dATP
5'_[a32p] triphosphate (3000 Ci/mmol, Amersham); and 2Jll of Klenow
enzyme. Autoclaved distilled water was added to give a final volume of
50Jll. The labelling reaction was carried out at 37°C for a period of 4
hours. The percentage of dATP 5'_[a32p] triphosphate incorporated into
the probe was determined at the end of this period by spotting IJ.L].of
reaction mixture onto each of two glass fibre discs. The dices were placed
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in scintillation vials and the ~ emission counted by Cerenkov analysis
in a 1900CA Packard liquid scintillation analyser. The glass fibre discs
were washed under vacuum filtration with ice cold 10% trichloroacetic
acid and their ~ emission recounted.
CIO.1 Specific activity of labelled probe
Specific activity of labelled probe = [KI't] x 103 dpm/ug; where 1(
represents the amount of radioactive incorporation (dpm), and 't
represents the total amount of probe DNA (ng).
1( = total JlCi x 2.2x104 x percentage incorporation.
't = [Total jlCi x 13.2 x percentage incorporation]l[number of dNTPs x
their average specific activity] + original amount of probe DNA (ng).
ell Prehybridisation solution
10rnl distilled water; lOml of 50xDenhardt's solution (see section C11.1);
25ml of 20x sse (see section C11.2); 2ml ofPB (see section C11.3); 3ml
of a 10 mg/m1 herring sperm DNA solution; 50ml of deionised
formamide.
ClI.I 50x Denhardt's solution
1% ficoll; 1%polyvinylpyrrolidone; 0.5% bovine serum albumin. Make up
in autoelaved distilled water.
CII.2 20x Standard saline citrate
3.0M NaCl; 0.3M tri-sodium citrate. Make up in autoclaved distilled
water.
CIl.3 Phosphate buffer (pH 6.56)
1M Na2HP04.12H:.'O; 1M NaH~04.2H20. Make up in autoclaved
distilled water.
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